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Abstract 
The success of combined antiretroviral therapy has transformed Human 
immunodeficiency virus (HIV) infection from an acute and life-limiting condition to an 
enduring but treatable illness, marked by fluctuations in HIV-related health 
consequences and co-morbidities. HIV-associated neurocognitive disorders (HAND) 
are one such possible consequence and are of particular concern in light of their 
sustained high prevalence in people with otherwise well-managed HIV infection. 
Given the neuropsychological profile of HAND (affecting frontostriatal brain regions 
and associated executive functions), it has been suggested that HAND may have 
implications for social cognition; that is to say, the cognitive capacities that facilitate 
social interaction. Thus, the current study aimed to explore social cognitive 
performance in the neuropsychological profile of HAND. 
A diverse HIV-positive cohort  (N=16), recruited across two outpatient services, were 
administered the Social Stories Questionnaire (Lawson, Baron-Cohen, & 
Wheelwright, 2004), Reading the Mind in the Eyes Test (Baron-Cohen, Wheelwright, 
Hill, Raste, & Plumb, 2001), and the Questionnaire of Cognitive & Affective Empathy 
(Reniers et al., 2011), alongside a standard neuropsychological battery. Using IMB 
SPSS v22, an exploratory group-level bivariate correlational analysis compared 
group scores against published normative data, and further Individual Profile 
Analyses explored cognitive differences within rather than across individuals to 
investigate trends not apparent at group-level. 
The sample demonstrated reliable performance weaknesses on both tests of social 
cognition (RMET and SSQ), independent of executive function and in the absence of 
global of specific impairments. Individual Profile Analyses revealed that these 
impairments were unrelated to stage of infection and occurred alongside (not before) 
cognitive decline in other core domains. Recommendations for further research are 
offered, drawing upon a critical review of the methodology employed. Clinical 
implications include; suggestions for increasing professional curiosity and empathy; 
psychoeducation; and the role of clinical neuropsychology in contributing to the 
development of the wider understanding of the potential emotional and behavioural 
sequelae of HAND. 
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1. INTRODUCTION 
A literature review was conducted to provide a comprehensive background of the 
literature in the field of HIV infection and treatment and identify and summarise the 
relevant research regarding social cognition in HIV-associated neurocognitive 
disorders (HAND). A ‘narrative approach’ to this endeavour was taken as it 
presented a suitable method with which to efficiently review the vast and rapidly 
evolving literature characteristic of this particular field. Key terms relevant to the 
research area (e.g. ‘HIV’, ‘HAND’, ‘cognitive impairment’, ‘social cognition’, and 
‘social functioning’) were entered into literature databases (PsychInfo, Pubmed and 
Science Direct); available abstracts were screened for appropriate themes and 
where appropriate full articles obtained. Due to the minimal research into social 
cognition impairments in HAND, the search was broadened to include research into 
social cognition in further neurological conditions in which the prefrontal cortex is 
implicated, including frontotemporal dementia (FtD) and Autism Spectrum Conditions 
(ASC). 
Before moving onto the literature concerning social cognition and HAND, a brief 
history of HIV will be provided, with signposting to further information where 
necessary, to provide the necessary contextual framework for the current study.  
1.1. The Human Immunodeficiency Virus (HIV) Epidemiology 
1.1.1.  HIV Virology and Transmission 
The Human Immunodeficiency Virus (HIV) is a retrovirus that affects the cells of the 
immune system, leading to progressive deterioration in immunity and increased 
susceptibility to opportunistic infections, diseases and cancers. The strength of an 
individual’s immune system can be detected by laboratory tests and reported as the 
‘CD4 count’. This test is a measurement of CD4+T lymphocyte cells in specific blood 
sample; determining the extent to which HIV has depleted the glycoprotein 
molecules on the surface of immune cells (Bartlett, 2000; Hazenberg, Hamann, 
Schuitemaker, & Miedema, 2000).  
The virus is transmitted between humans through the transfer of infected bodily 
fluids. In the UK, this process occurs most commonly through unprotected sexual 
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intercourse, transmission of contaminated blood (blood transfusions), sharing of 
contaminated needles, and between mother and infant during pregnancy, childbirth 
and breast feeding (Kumar & Clark, 2012). If left untreated, HIV can take on average 
ten years to develop into acquired immunodeficiency syndrome (AIDS); a condition 
characterised by a CD4 count below 200cells/mm3 and increased vulnerability to 
potentially life-limiting infections and cancers.  
The concept of ‘episodic disability’ was developed by O’Brien et al. (2008) in 
conjunction with service-users in an effort to develop a comprehensive framework for 
understanding the health related consequences of living with HIV. This phrase 
reflects how HIV is characterized by unpredictable periods of wellness and illness: 
the concept of ‘disability’ reflects the real-life impact and health-related setbacks that 
can occur due to HIV and its associated treatments, and the term ‘episodic’ reflects 
the fluctuations of said experiences. 
The cluster of cognitive impairments conceptualised as ‘HAND’ are one of the many 
possible consequences of HIV infection. However, contrary to the majority of HIV 
associated and AIDS-defining illnesses, the cause and temporal progression of 
neurocognitive impairment remains complex and unclear; equivocally linked with 
individual CD4 levels and HIV virology. Whilst some studies report a modest 
association between CD4 counts and neurocognitive impairments (Bornstein et al., 
1991; Childs et al., 1999; Stern et al., 1991), others have failed to find a relationship 
(Miller et al., 1990; Yaakov Stern, 2001). A comprehensive understanding of why 
HAND occurs, and the difficulties in treating HIV virology are required and presented 
throughout the introduction.  
1.1.2. Worldwide and National Prevalence  
The United Nations programme on HIV/AIDS (UNAIDS) estimated that, worldwide, 
there are approximately 36.9 million people living with HIV worldwide. Within the last 
year, around 2 million people were newly diagnosed, and 1.2 million people who died 
from AIDs-defining illnesses (UNAIDS, 2015).  
Relative to this global prevalence, the UK has a relatively small HIV epidemic, with 
103,700 people believed to be living with HIV, of whom 69,200 were men and 34,000 
women (Public Health England, 2015a)(Public Health England, 2015a). This equates 
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to a national prevalence of 1.9 per 1000 people (aged 15 and over), a statistic which 
has gradually increased since 1990, reflecting the advancements in medical 
treatment and subsequent improved life expectancy; ongoing viral transmission; 
steady numbers of new diagnoses; and a gradual rise in sexually transmitted 
diseases in the wider sexual health context. 
An estimated 17% (18,100) of people living with HIV in the UK are believed to be 
unaware of their infection status; at risk of unmedicated viral replication and naive 
transmission. However, this number has gradually declined from 25% in  2010, 
following targeted public health initiatives (Public Health England, 2015a, 2015b). 
1.1.3. Natural History of HIV 
There are two main strains of HIV; HIV-1 and HIV-2. Each have different origins and 
evolutions, and are believed to be the result of multiple cross-species transmissions 
and the subsequent mutations of the simian immunodeficiency viruses (SIVs); 
present in African primates well before the emergence of HIV in the Human species 
(Sharp & Hahn, 2011; Worobey et al., 2010).  
HIV-1 has been found to be closely related to the SIV-cpz strain found in 
chimpanzees, who may have developed the virus after consuming smaller species of 
animals, themselves infected with two different SIV strains which may have mutated 
into a third strain able to pass between chimpanzees and humans (Bailes et al., 
2003; Sharp & Hahn, 2011). Less infectious and far rarer than HIV-1; HIV-2 is 
instead closely related to a strain of SIV found in sooty mangabeys monkeys (Chen 
et al., 1997). However, it is HIV-1 that is widely accepted as the principal cause of 
the AIDS pandemic, responsible for the vast majority of global HIV infection cases 
today.  
It is believed that both HIV-1 and -2 may have been transferred to human by means 
of the handling and consumption of infected meat; known as the “hunter” hypothesis. 
Sharp and Hahn (2011) suggest that in most cases the “hunters” own immune 
response would have been successful in fighting off the SIV infection, but on a few 
occasions the virus must have managed to adapt itself within the new human host, 
mutating into HIV-1, in most incidences.  
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The first transmissions of SIV-cpz to HIV-1/2 in humans may have occurred as early 
as 1920, in Kinshasa in the Democratic Republic of Congo (Faria et al., 2014). At 
which time, specific social factors are believed to have contributed to the conditions 
in which rapid transmission of the virus between people in the area was made 
possible, including, for example, the thriving railway transport system which saw over 
one million people travel through Kinshasa each year: facilitating the spread of the 
virus and the consequential development of the global pandemic (Faria et al., 2014).   
However, HIV did not receive global attention until the 1980’s in the USA, when a 
pattern of rare diseases including Pneumocystis Pneumonia and Kaposi’s Sarcoma 
were reported among a group of men (Hymes et al., 1981). The term ‘AIDS’ first took 
form to describe this pattern of unexpected opportunistic infections and diseases in 
1982 and, a year later, these become seen as ‘secondary infections’ following the 
progression of a primary infection of HIV. First named HTLV-III/LAV (human T-cell 
lymphotropic virus-type III/lymphadenopathy-associated virus) the virus later became 
known as HIV. 
1.1.3.1. Alternative Perspectives 
For the last three decades, prominent disagreements have existed with regards to 
the HIV and AIDs phenomenon. Although subsequent advancements in research 
and medicine have led to some of these alternative theories being discredited, 
dissention remains, with a wide range of critiques and alternative theories to the 
dominant hypothesis offered. Goodson (2014) reviews and summarises the key 
disputes into four categories, including; retroviral molecular markers; transmission 
electron microscopy; images of retroviral particles; efficacy of anti-retroviral drugs; 
and epidemiological data. It is beyond the scope of this study to further discuss these 
factors but, as noted by Goodson (2010), the acceptance of uncertainty and 
awareness of divergent ideas and perspectives is an important part of scientific 
enquiry, and a duty for health professionals in ensuring that clinical practice is 
grounded in rigorous scholarly and ethical standards. 
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1.2. HIV Treatment 
1.2.1. Antiretroviral Therapy 
The primary treatment for HIV infection is currently combined antiretroviral therapy 
(cART), a pharmacological medication which slows down, and thus controls, the 
harmful effects of the virus on the immune system. In order for cART to have a 
powerful and long-lasting effect against HIV it is sometimes necessary to take a 
combination of three or more types of cART. Effective cART can suppress viral 
replication in the blood to the extent that HIV becomes undetectable. This event 
improves individual health outcomes and diminishes risk of transmission. In 2014 in 
the UK, 91% of people diagnosed HIV infection were on antiretroviral treatment 
plans, with 95% of them achieving undetectable viral loads. Therefore, the advent of 
cART in 1996 and the subsequent medical advancements have radically changed 
the prognosis and health outcomes of living with HIV infection in the UK: whereas a 
diagnosis of HIV once meant death, the estimated life expectancy for people with 
HIV infection (where cART is widely available) is now the same as the unaffected 
population (May et al., 2014). 
Currently, combined cART does not eliminate HIV from the body. This means, 
despite the otherwise successful treatment, people with HIV can have long standing 
latent HIV reservoirs where HIV RNA (viral load) can persist. This limits control over 
viral replication and disease prognosis, and necessitates the indefinite use of cART 
as part of a life-long treatment program (Gates & Cysique, 2016). Furthermore, 
adherence to cART is particularly important as reduced levels of the drugs in the 
person’s blood can re-enable viral replication and the development of resistance to 
the current drug and others like it (Hinkin et al., 2002; Levine et al., 2005).  
1.2.2. Commencing cART 
The recommended timing for commencing cART has been a widely contested topic. 
However, the British HIV Association (BHIVA, 2015) guidelines for the treatment of 
HIV positive adults now recommend that cART should commence as soon as 
possible after diagnosis. This guidance reflects the results of the large multicentre 
international RCT study called the ‘Strategic Timing of Antiretroviral Treatment' 
(START) study. Described by Gate and Cysique (2016, p. 5) as “the RCT needed to 
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settle the debate over benefits versus adverse effects of early cART”, the START 
study reported that people with a CD4 count of more than 500 cells pcm showed 
greater benefits from starting early cART than those whose CD4 count had fallen to 
350 cells pcm (The INSIGHT START Study Group, 2015). 
Gate and Cysique (2016) note early cART is not without its long term concerns in 
terms of cumulative toxicity and potential neuro/cardiotoxicity, as well as variable 
adherence level in different HIV populations. The authors also speculate that with 
more people starting treatment earlier, the clinical prevalence of HAND is likely to 
shift even further towards milder forms, highlighting the need for early detection 
standardised screening tools validated for longitudinal assessment. 
1.2.3. cART Toxicity and Adverse Side-effects 
Although cART regimens are essential for the effective treatment of HIV infection, 
the chemical compounds also have intrinsic toxicity causing adverse side effects as 
part of routine use including Hepatotoxicity; Hyperglycaemia; Hyperlipidaemia; Lactic 
acidosis; Lipodystrophy, Diarrhoea and Skin rashes (Macarthur, 2013; Mind 
Exchange Working Group, 2013).  
Such side effects have serious implications for treatment adherence. For example, 
non-infectious cART-related diarrhoea is a common side effect, occurring in 15% to 
20% of HIV patients. Diarrhoea can disrupt patients’ lives, negatively impacting 
quality of life, daily functioning and mood; significant factors contributing to whether 
individuals are willing and able to stick to strict medication regimes (MacArthur & 
DuPont, 2012). Supplementary treatments are emerging to treat certain cART-
related side effects, and recommendations have been offered to addressing the 
impact of such experiences on adherence in clinical practice (Chordia & MacArthur, 
2013; Macarthur, 2013). 
Some cART types have also been associated with impairments in 
neuropsychological performance (Ciccarelli et al., 2011) and mental health difficulties 
(Foster, 2003). Robertson et al. (2010) reported improved cognition for up to 96 
weeks in a group of immunologically and virologically stable people who elected to 
pause their cART regimens. The literature regarding the neurotoxic effect of cART is 
revisited later. 
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1.3. HIV-associated Neurocognitive Disorders (HAND) 
1.3.1. Nosology of HAND  
The terminology used to conceptualize HIV-associated changes to cognitive 
functioning has undergone substantial evolution since its initial characterization. Prior 
to 1991, a single disorder known as ‘HIV-associated dementia’ (HAD) captured the 
pathology of the observed cognitive impairment caused by severe immune 
suppression. The ‘minor cognitive motor disorder’ (MCMD) category was then 
introduced for patients with cognitive complaints who failed to meet the diagnostic 
threshold for HAD. Subsequently, with the introduction of the "Frascati Criteria," 
Antinori et al. (2007) proposed that existing classifications be revised into three 
tiered categories of impaired neuropsychological test performance and functional 
impairment under the umbrella term of ‘HIV-associated neurocognitive disorders’ 
(HAND). From most to least severe, the levels of impairment are; HIV associated 
dementia (HAD), Mild Neurological Disorder (MLD) and Asymptomatic 
Neurocognitive Impairment (ANI). A diagnosis of HAND requires acquired 
impairment in at least two cognitive abilities. HAD requires marked impairment, MND 
requires mild impairment, and ANI is clinically observable but does not interfere with 
daily function (Letendre, 2011). See Appendix A for further diagnostic criteria. 
Although this nosology is used widely in clinical and research settings, it has not 
been universally adopted. Critics argue that the relevant biological substrates, 
prognostic significance and therapeutic implications of the categories are not clearly 
established (Gisslén, Price, & Nilsson, 2011). A diagnosis of ANI can be awarded 
without evident functional impairment in daily living, based only upon an observed 
performance on formal neuropsychological testing. Gisslén, Price and Nilsson (2011) 
argue that this leads to over-estimated prevalence rates of neurological pathology in 
the normal HIV clinical population. However, Gates and Cysique (2016) argue that 
without the sensitive Frascati Criteria, the majority of HAND cases in cART-treated 
cohorts would be excluded from RCTs leading to a significant and far reaching 
impact on research into the neurocognitive consequences of HIV infection. Assuming 
that the global prevalence rates for mild HAND may represent ‘‘the tip of the iceberg’’ 
of HIV associated neuropsychological change, Gates and Cysique (2014) advocate 
for the inclusion of ANI and MND subtypes into RCTs and longitudinal studies for 
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monitoring and evaluation of treatment effects. Furthermore, a diagnosis of ANI is 
associated with a 2-fold increased risk of symptomatic HAND, as compared to a 
diagnosis of normal cognition (Sacktor et al., 2015). Neuropathological changes 
often precede the onset of neurodegenerative disorders by decades and build up 
slowly over time (Jansen et al., 2015), and this provides evidence for the clinical 
value of ANI in assessment and early intervention in HAND, enabling targeted and 
timely care provision.  
1.3.2. Prevalence 
In the pre-cART era, severe cognitive impairment was common in individuals with 
HIV infection and affected up to 50% of patients before death (Grant et al., 1987; 
Nightingale et al., 2014). At that time, HAD was a progressive disorder leading to 
death within months. However, since the advent of cART, prevalence estimates for 
HAD have fallen from 16% (McArthur et al., 1993) to less than 5% (Heaton et al., 
2010).  
Milder subtypes of HAND have, in contrast, persisted and increased in incidence 
alongside the reduced mortality of HIV (Heaton et al., 2011). These expressions of 
HAND appear in the earlier stages of infection, which, in line with cART slowing 
down the progression of the illness, is a period of time that is maintained for much 
longer then before (Heaton, Clifford, & Franklin, 2011). The persistence and 
progression of cognitive impairment in the cART era is well supported by brain 
imaging studies which show the continued deleterious impact of HIV infection on the 
brain in the post-cART era (Harezlak et al., 2011; Hua et al., 2013)  
In a large (N=1555) diverse sample of people with HIV infection, Heaton et al. (2010) 
reported that 52% of the sample had some form of HAND. This estimate broke down 
into 33% with ANI, 12% with MND, and 2% with HAD. In comparison to this, in the 
more recent Multicentre AIDS Cohort Study (MACS), Sacktor et al. (2015) reported 
overall prevalence rates of 25%–33% of HAND. This is somewhat lower than that 
observed in the aforementioned study, but may reflect demographic and clinical 
differences among these cohorts.  
As such, although the exact prevalence estimates of mild forms of HAND vary 
depending on the population and neurocognitive tools and definitions used 
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(Nightingale et al., 2014), it is widely acknowledged that mild forms of HAND remain 
a significant problem for patients whose HIV is otherwise well controlled. 
Consequently, disruption to everyday neurocognitive functioning is one of the most 
common complications experienced by people with HIV (Sanmarti et al., 2014).  
1.3.3. Neuropathogenesis of HAND  
There is no single causal biological mechanism behind the neurocognitive 
consequences of HIV infection. The primary hypothesis concerns the impact of HIV 
on the central nervous system (CNS), one of the target systems where HIV can be 
detected. Soon after primary infection, HIV RNA may cross the blood brain barrier 
(BBB). HIV RNA concentrations can then accumulate, leading to HIV-related 
neuropathology. In untreated HIV replication, the BBB becomes increasingly 
permeable, allowing the crossing-over of many cell types. This may, in part, explain 
the greater prevalence of HAD in the pre cART era and why - since cART has 
successfully controlled HIV RNA replication - HAD has decreased in frequency and 
severity  (Heaton et al., 2011). Gates and Cysique (2016) note that further research 
is needed to determine how relevant this model is for accounting for the 
neuropathology of HIV in the context of long-term virally suppressed HIV infection 
and cART exposure.   
A further theory of HIV neuropathogenesis looks at the differential levels of HIV RNA 
located in the cerebrospinal fluid (CFS) and the blood, following evidence that the 
virus can be detected in the CFS in the absence of comparable levels in the blood 
(Canestri et al., 2010; Edén et al., 2010). Termed CFS ‘viral escape’ (Ferretti, 
Gisslen, Cinque, & Price, 2015); the cause of this phenomenon has been attributed 
to insufficient ‘CNS penetration effectiveness’ (CPE) of cART to areas in the CFS 
where HIV replication has occurred. This hypothesis has been used to explain the 
sustained prevalence of milder subtypes of HAND, and had led to a surge of 
research into higher CPE cART regimes based on the assumption that these will 
proffer better cART treatment results with reduced prevalence of mild HAND. 
However, few studies have since supported this assumption (Smurzynski et al., 
2011; Sterne et al., 2009) and the actual levels of HIV needed in the CNS in order for 
HAND to develop is currently unknown. Studies have shown that HAND can develop 
and progress despite viral suppression in both the blood and CSF in 10–30 % of 
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cases (Antinori et al., 2007; Canestri et al., 2010).  Cross et al. (2013) investigated 
the differential cognitive outcomes of people using ARTs with different CPE levels, 
for one year. Participants treated with cART were more likely to maintain or improve 
cognitive function compared to those without cART, but there was no difference in 
cognitive outcomes based on CPE levels. Furthermore, in some cases, high CPE 
cART have been associated with increased cognitive impairment (Ciccarelli et al., 
2011; Marra et al., 2009; Reust, 2011); higher rates of HIV dementia (Caniglia et al., 
2014); and other adverse side effects including: sleep disturbances, abnormal 
dreams, depression, fatigue, vomiting, fever, and headaches (Reust, 2011).  
Decloedt, Rosenkranz, Maartens and Joska (2015) reviewed the multiple 
mechanisms which may affect the CPE of cART, concluding that the relationship 
between CPE and virological control is non-linear, multifaceted and dependant on 
numerous factors. Accordingly, there remains a consensus in the literature that the 
clinical relevance of CSF viral escape hypothesis is not yet well understood, and it is 
unclear what persistent levels of HIV RNA in the CSF mean for the development of 
HAND (Gates & Cysique, 2016).  
As well as viral replication, there are many other factors that may contribute to HAND 
pathogenesis, including the role of intrathecal inflammation (Cysique et al., 2013; 
Gongvatana et al., 2013; Harezlak et al., 2011) and the interaction between chronic 
immune activation and aging on the CNS (Cysique, Bain, Brew, & Murray, 2011). 
Furthermore, where cART is widely available, drug resistance, poor adherence, and 
phenomenon of cART neurotoxicity (Berger & Clifford, 2014) are all factors which 
may contribute to or intensify the pathogenicity of HIV and the development of neuro-
cognitive impairment (Patel et al., 2013).  
The relationship between the potential neurotoxic effects of cART and the 
development of milder forms of HAND is still relatively unclear. Although cART has 
seen an irrefutable reduction in the more severe forms of HAND, its function as 
either a protective or causal contributing factor in the development of the milder 
forms of HAND is an ongoing debate. While some studies report modest 
improvements in neurocognitive function in people with HAND after starting 
antiretroviral treatment (Al-Khindi, Zakzanis, & van Gorp, 2011; Cohen et al., 2001; 
Cysique et al., 2010; Tozzi et al., 2007) other studies contend that the cART has a 
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negative impact on cognitive function (Ciccarelli et al., 2011; Robertson, Liner, & 
Meeker, 2012) or no impact at all on mild neurocognitive impairment (Kore et al., 
2015). Such inconsistencies are partly due to the fact that variables in the medical 
field have, up until now, been in a state of constant change and therefore hard to 
measure. Furthermore, it is difficult to differentiate potential universal negative side 
effects from health issues caused by the HIV infection itself interacting with the social 
determinants of health.  
1.3.4. Onset and Temporal Progression of HAND 
HIV infection may start affecting neurocognitive function immediately after infection 
(Reger, Welsh, Razani, Martin, & Boone, 2002; Sacktor & Robertson, 2014; 
Weintraub, Wicklund, & Salmon, 2012), however, unlike many other 
neurodegenerative conditions such as Alzheimer’s and Huntingdon’s diseases, 
HAND is not invariably progressive. Indeed, Heaton et al. (2015) reported that there 
are variable clinical trajectories in HAND, stating that neurocognitive change is 
common and people may demonstrate considerable recovery of cognitive functions, 
decline, or static impairment.   
1.3.5. Treatment of HAND  
Gates and Cysique (2016) report that no individual agent or specific treatment plan 
has unequivocally yielded benefits for treating or preventing HAND. However, given 
that advanced immunosuppression remains the strongest correlate of neurocognitive 
impairment (Heaton et al., 2010; Heaton et al., 2011), the primary treatment of 
HAND follows the aforementioned BHIVA guidelines (i.e., promptly commencing 
cART) to control viral replication and boost immune health.  
Weber et al. (Weber, Blackstone, & Woods, 2013) note that, over the last two 
decades, the treatment of HAND has fallen in the shadow the of the virological 
management of HIV infection. The authors elucidate the relative sparsity of research 
investigating the efficacy of cognitive rehabilitation for HIV-associated neurocognitive 
impairment and advocate for the development, validation, and clinical deployment of 
cognitive neurorehabilitation interventions tailored to the needs of persons living with 
HIV. Although such efforts can be seen in recent studies by Livelli et al. (2015), and 
Casaletto et al. (2016), which report positive findings with regards to the potential for 
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neuropsychological techniques to manage and improve cognitive impairments in 
HAND, this remains a new and emerging field of treatment. 
1.4. HAND co-morbidities 
Over 90% of individuals with HIV infection are believed to have some form of co-
morbidity, including a range of medical, psychological, and co-morbid conditions 
(Heaton et al., 2009, 2011). The Antinori et al. (2007) online supplement provides 
detailed guidelines for classifying the most commonly encountered co-morbid 
conditions experienced by people with HAND, and whether they should be 
considered incidental, contributing, or confounding with regards to their impact on 
HAND.  
Gates and Cysique (2016) highlight the complex and idiosyncratic interaction 
between HAND and co-morbidities, emphasising that although certain co-morbidities 
may suggest a non-HIV cause for cognitive impairment, they may also compound or 
interact HIV’s effect on the CNS in a more complex nuanced manner. This marks a 
shift in focus away from the more traditional clinical practice of ‘identify and separate’ 
‘pure HAND’ from co-morbidities, to an acknowledgement of the fluctuating and 
interactional nature of HIV chronicity, co-morbidities and HAND. This view is in 
keeping with the aforementioned concept of ‘episodic disability’ (O’Brien et al., 
2008). 
1.4.1. HAND; Social Co-morbidities  
HIV infection is most prevalent in under resourced and economically marginalized 
and oppressed global areas. Although cART is considered the universal gold 
standard of HIV treatment, access to said treatment in areas with the greatest 
prevalence remains the most limited.  It is beyond the scope of this study to pay 
credence to the geopolitical context in which this longstanding inequality occurs, but 
an awareness of the global disparity is fundamental to an understanding of why, in 
considering the HIV-related health consequences, social co-morbidities are a 
substantial factor. Indeed, Tedaldi et al. (2015) advocate that HAND literature should 
focus on the intersectional nature of physical and social co-morbidities in a global 
assessment schema.  
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1.4.1.1. Educational Experience and Culture 
Due to inherent cultural biases within the test materials, individuals from certain 
racial and ethnic groups can disproportionately obtain lower scores on a broad range 
of cognitive assessment task in comparison to their counterparts (Bernard, 1989; 
Gurland, Wilder, Cross, Teresi, & Barrett, 1992; Manly et al., 1998). This puts said 
groups at risk of incorrect test interpretation and false-positive diagnoses following 
test administration (Manly et al., 2011). In view of this, ‘education attainment’ has 
been used as a way of accounting for these differences, as it is an additive life 
experience which relates to many of the biases in test materials, and varies between 
different demographic groups. Furthermore, it has been shown to have a significant 
impact on neuropsychological test performance.  
Educational attainment can be quantified using ‘total years of education’ or ‘quality of 
education’ (as assessed using reading ability). However, the latter has been shown 
to be a stronger predictor of cognitive performance in groups most commonly 
affected by this phenomenon (Dotson, Kitner-Triolo, Evans, & Zonderman, 2008, 
2009), and has been reported to account for a large proportion of the variance in 
tests of psychomotor speed and executive function between participants with and 
without HIV infection (Manly et al., 2011).  
More structural efforts to address said cultural and educational biases were made by 
Manly et al. (2011) who sought to collect and develop more appropriate normative 
data for selected neurocognitive tests using a large group of ethnically and 
educationally diverse HIV-uninfected, high risk women, as well as their HIV-infected 
counterparts. 
1.4.1.2. Poverty and Trauma 
Tedaldi et al. (2015) note that poverty and exposure to adverse life experiences may 
deplete the ‘cognitive reserve’ of people prior to contracting HIV. The cognitive 
reserve hypothesis is the notion that humans have extensive neuronal connections 
that can protect neurons when they are subjected to injury through oxidative stress 
or inflammation. The available protection can be influenced by positive or negative 
neuroplasticity (Patel et al., 2013; Vance, Fazeli, Grant, Slater, & Raper, 2013). This 
hypothesis may be particularly relevant for the global population of people living with 
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HIV, of whom so many are from impoverished living conditions, with exposure to 
limited social resources, violence, and cumulative traumatic experiences (Spies, 
Fennema-Notestine, Archibald, Cherner, & Seedat, 2012). If life experiences can 
erode neurocognitive reserves, then impairment occurring in the context of HIV 
infection may occur as a result of pre-existing idiosyncratic cognitive decline. This is 
supported by a study by Troeman et al. (2011) where childhood trauma was 
demonstrated to have an impact on functionality and quality of life for people living 
with HIV infection. 
1.4.1.3. Stigma  
In one of the first studies to consider the contextual factors that contribute to the 
experience of living with HIV, O’Brien et al. (2009) exposed the continued impact of 
stigma in exacerbating people’s experience of HIV-related disability.  People with 
HIV-infection reported experiencing stigma from family, work colleagues, employers 
and health care providers due to their HIV status, sexual orientation, ethno-cultural 
background, employment status and/or gender. These experiences were reported to 
be associated with problems such as low self-esteem, elevated stress, anxiety and 
depression, and shame and embarrassment, and present barriers to social inclusion, 
for example; inability to work, and difficulty initiating or maintaining personal 
relationships (O’Brien et al., 2009). Experiences of stigma have been shown to 
exacerbate depression for those living with HIV (Relf & Rollins, 2015) as well as 
intersect with other forms of discrimination (Galvan, Davis, Banks, & Bing, 2008), 
and contribute to negative plasticity in the cognitive reserve hypothesis.  
1.4.2. HAND; Physical Co-morbidities  
1.4.2.1. Age  
Although individuals with HIV infection are now able to live longer healthier lives than 
in the pre-cART era, as yet, little is known about the impact of ageing on HAND. One 
prediction is that the prevalence of HAND will continue increase alongside people 
with HIV living longer (Gates & Cysique, 2016; Heaton et al., 2015; Kupprat et al., 
2015). 
15 
 
Valcour et al. (2004) highlighted the unique health concerns of older people, 
specifically noting the cumulative neurotoxic effect of cART, and its interaction with 
aging, immune activation, and HIV associated co-morbidities.  In this study, older 
participants were found to have higher rates of HIV associated dementia (HAD), less 
resilient immune systems, and higher rates of other co-morbidities related to HIV and 
medication side effects, than other HIV age cohorts. 
Gate and Cysique (2016) state that the ageing process may have the potential to 
actually alter the profile of neurocognitive deficits in HAND, either by accelerating 
HIV-related neurocognitive decline, or by involving new cognitive deficits not typical 
of HIV-related brain injury.  
1.4.3. HAND; Psychological Co-morbidities  
Rates of anxiety and depression in people living with HIV are common, with 
prevalence as much as two to three times higher than those observed in the general 
population (Tucker, Burnam, Sherbourne, Kung, & Gifford, 2003), and higher than 
any other mental health difficulty in people living with HIV (Nakasujja et al., 2010). 
Such difficulties can interact with the demands of coping with, and managing, a long-
term health condition in a multitude of ways. For example, the difficulty in structuring 
daily life and following strict treatment plans can lead to increased rates of 
medication non-adherence, which in itself can lead to worse health outcomes, 
neurocognitive impairment and increased mortality (Ammassari et al., 2004; Anand, 
Springer, Copenhaver, & Altice, 2010). 
The prevalence of HIV infection in people with a diagnosis of ‘schizophrenia’ is 
higher than the general population, estimated to be between 4% and 23% (Cournos 
& McKinnon, 1997; Perälä et al., 2007). Furthermore, both ‘schizophrenia’ and 
‘bipolar’ disorder are higher in people with HIV-infection who also have substance 
misuse problems, and those who are from lower socio-economic backgrounds 
(Tedaldi et al., 2015) . The psychological experiences associated with such 
diagnoses have been shown to have a profound and complex interaction with 
cognitive functioning, either directly or indirectly as a result of neuroleptic medication 
(Kasper & Resinger, 2003).  
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1.5. Neuropsychology of HAND 
1.5.1. Neuropsychology Assessment  
Neuropsychological assessment is a performance-based method of assessing 
cognitive function. It is used to examine the observable cognitive consequences of 
brain damage and disease, and has several specific uses including collection of 
differential diagnostic information, assessment of treatment response, prediction of 
functional potential, and identification of rehabilitation and recovery treatment plans 
(Harvey, 2012).  
Despite the unprecedented developments in brain imaging technology which have 
enabled researchers to look inside the active living brain to observe changes in brain 
structure and function, it remains the case that the presence of severe brain changes 
can be associated with nearly normal cognitive functioning, while individuals with no 
such lesions can have substantial cognitive and functional impairments. As such, 
clinical neuropsychological assessment continues to be of significant clinical value, 
both as a research method and a clinical assessment tool. Woods et al. (2009) 
advocate that the neuropsychological approach has particular value in HIV care, 
elucidating the component processes and cognitive mechanisms of HAND and 
informing clinical understanding and contributing towards the development of 
targeted therapeutic interventions.  
1.5.2. Assessment Tools for HAND  
The HIV Dementia Scale is shown to reliably identify people with HIV infection who 
are suffering with HAD, but has limited ability to detect ANI and MND (Sacktor et al., 
2005).  The Montreal Cognitive Assessment (MoCA) has also been trailed for use 
with people with HIV, and although a valid brief measure, it too lacks the sensitivity 
to differentiate the milder HAND categories (Chan, Kandiah, & Chua, 2012; Kim et 
al., 2016; Overton et al., 2013). At present, The Mind Exchange Group (2013) 
guidelines (the product of an evidence-based process to develop and consolidate 
practical guidance for the screening, diagnosis, treatment and prevention of HAND) 
recommend the use of the MoCA to identify individuals who may subsequently 
require formal neuropsychological testing. 
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Alternative methods of assessing the impact of cognitive impairment include efforts 
to ascertain “real world” functioning, such as self- or informant reports.  However, 
information gathered in this way is vulnerable to several factors, including, mood; 
impaired self-awareness; and, variability in subjective perspectives. For example, 
those with low mood may over-report deficits that are not objectively apparent 
(Millikin, Rourke, Halman, & Power, 2003) due to negatively biased thoughts and 
rumination (Baert, De Raedt, & Koster, 2010). Alternatively, problems may be under-
reported, by patients or informants due to a conscious or unconscious desire to 
minimize the problem. Accordingly then, neurocognitive testing offers the opportunity 
to gain from the richness of self-report information as part of a ‘clinical interview’, and 
then corroborate such information against performance on standardised tests.  
The Mind Exchange Working Group (2013) guidelines advise that all patients with 
HIV should be screened for HAND as early as possible in their disease; however, 
such assessments are often unavailable in outpatient settings, and specialist HIV 
services vary in the extent to which they offer in-house assessments or refer 
externally for service provision.  
The lack of routine and standardised assessments for HAND has implications for 
people with HIV infection and health services. Services without routine screening 
assessments are unable to track the development of HAND in individuals with HIV 
infection, leaving them unable to monitor the impact of cART, as well as the complex 
interaction between the multiple risk factors for cognitive impairment.  
1.5.3. Neuropsychological Profile of HAND 
Although each person’s brain is affected by HIV in a different way, the region’s most 
commonly affected appear to be the basal ganglia and the hippocampus, the frontal 
neocortex and the white matter tracts connecting these regions, and the cerebellar 
grey matter of the mid-frontal cortex (Wiley et al., 2006).  
Younger and middle-aged adults typically display a ‘‘subcortical’’ cognitive profile of 
bradykinesia, bradyphrenia, executive dysfunction, and deficient memory encoding 
and retrieval (Heaton et al., 1995). Some researchers have queried whether the 
development and expression of HAND in older adults might display a more ‘cortical’ 
profile (e.g., temporal and parietal lobe) than that seen in younger people with HIV 
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infection, following evidence of pathology in HIV-infected individuals that may be 
similar to that observed in traditional “cortical” dementias (Ances et al., 2010; 
Gelman & Schuenke, 2004). However, this remains a controversial hypothesis and 
the research is yet unclear, with both Iudicello et al. (2012) and Scott et al. (2011) 
finding that the combined effects of HIV and aging did not result in a ‘‘cortical’’ 
pattern of cognitive deficit. 
There is substantial variability in clinical expressions of HAND and the spectrum of 
impairments characteristic of HAND have evolved alongside the sustained aviremia 
and immune recovery following effective cART. In this changing context, further 
research is required in order to ascertain a distinctive pathophysiological mechanism 
or diagnostic pattern of HAND (Dawes et al., 2008). That said, the literature reports 
general trends of particular impairments, as outlined below. 
Twenty-five years ago HAND presented as a severe motor and cognitive disorder in 
patients at advanced stages of infection, whereas now it typically manifests as milder 
and more common disturbances of psychomotor speed, processing speed, executive 
function, or memory (Heaton et al., 2010; Spudich, 2013). These trends are 
supported by the findings of a study by Heaton et al. (2011) which compared the 
characteristics of HAND in pre- and post-cART eras. The authors reported that pre-
cART HAND saw impairments mostly in motor skills, processing speed, and verbal 
fluency, whereas post-cART era has seen an increase in learning and memory and 
executive function impairments.  
The literature regarding the impact of HIV-infection on these specific areas and core 
domains is discussed below. Whilst the following sections have been artificially 
separated to enable a clear overview of the current literature, optimal performance of 
any particular cognitive ability typically requires multiple cognitive abilities to be intact 
for successful execution. Furthermore, the researcher acknowledges the socially 
constructed nature of these terms, and seeks to employ them as part of a pragmatic 
endeavour rather than as part of an essentialist discourse.  
1.5.3.1. Attention and Working Memory 
Attention is a multifaceted ability that involves the capacity to orientate oneself and 
maintain and shift focus in the context of multiple stimuli (Iudicello et al., 2008) and 
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attention deficits in HAND are thought to be among the earliest to develop (Butters et 
al., 1990; Heaton et al., 1995; Levine et al., 2008). 
Heaton et al. (1995) used six neuropsychological measures to assess attention. 
Using a principal components analysis, the authors determined that the key 
underlying factors common among the multiple measures were “Attention/Speed of 
Processing” (as assessed by Digit Symbol, Digit Vigilance time, Trails Making Test 
Parts A & B) and “Attention/Working Memory” (as assessed by Digit Span). Thus 
suggesting that attentional factors were multifactorial and closely related to 
processing speed and working memory.  
1.5.3.2. Motor Skills and Information Processing Speed 
Woods et al. (2009) note that bradykinesia (i.e., slowed movement) and 
bradyphrenia (i.e., slowed information processing) are cardinal symptoms of HAND 
and may even underlie deficits observed in other neurocognitive domains.  
Both conditions are characteristic of HAD, and used to be commonly observed in the 
pre-cART era, alongside impaired rapid eye movements, reduced gait velocity, 
hyper-reflexia and release signs (Heaton et al., 2011; McArthur et al., 1993). Whilst 
bradykinesia-associated impairments have drastically declined in the post-cART era 
(Baldewicz et al., 2004), bradyphrenia- associated impairments appear to have 
sustained a high prevalence in HAND. Within this context, it is important to note that 
the assessment and measurement of information processing ability is complicated by 
the ill-defined nature of ‘information processing speed’ and difficultly separating out 
impairments in this, from other areas, such as attention or working memory.  
In a longitudinal study, Baldewicz et al. (2004) reported the participants with HIV 
scored lower than controls on tests of information processing throughout the course 
of the study. Further, Fellows, Byrd and Morgello (2014) assessed information 
processing speed in a sample of racially and ethnically diverse men and women 
living with HIV/AIDS and concluded that reduced information processing speed may 
be seen as a primary deficit in HAND, which may also account for other HAND 
impairments.  
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As identified above, information processing speed is closely related to attention 
(Levine et al., 2008). Both processing speed and attention are believed to have a 
fundamental role in supporting higher order skills, and impairment in these areas can 
result in deficits in other cognitive domains (Levine et al., 2008). 
1.5.3.3. Learning and Memory 
HAND is commonly associated with impairments in episodic memory and explicit 
memory (Iudicello et al., 2008; Woods et al., 2009). Mild to moderate deficits in 
episodic memory are common in the early stages of HAND in both verbal and visual 
memory tasks (Woods et al., 2009). Intermediate memory and semantic memory, in 
contrast, remain relatively intact, with deficits not appearing until the more severe 
stages of HAND (Heaton et al., 1995, 2004). As such, it appears to be difficulties 
involved in the process of learning new information which is characteristic of the 
profile of HAND, whereas learned information is often retained (Woods et al., 2009).  
1.5.3.4. Executive Function  
Executive function refers to a wide range of complex cognitive skills including 
abstract reasoning, evaluation, decision-making, planning, organising, set shifting 
and inhibiting automatic responses. These are associated with frontal lobe function; 
including (but not limited to) the frontal cortex, the basal ganglia and the posterior 
parietal cortex (Poletti, Enrici, & Adenzato, 2012; Stuss & Levine, 2002). 
Impairments in executive functioning are common and central to HAND in the cART 
era (Reger et al., 2002). HAND studies have consistently shown deficits in 
abstraction and problem solving (Heaton et al., 1995), inhibition (Hinkin, Castellon, 
Hardy, Granholm, & Siegle, 1999), set switching skills (Carter, Rourke, Murji, Shore, 
& Rourke, 2003; Reger et al., 2002) and social planning (Benedict, Mezhir, Walsh, & 
Hewitt, 2000).  
Verbal fluency, another constituent of executive function, is also a substantial and 
common area of impairment in HAND, and has been so since the pre-cART area 
(Heaton et al., 2011). Rippeth et al. (2004) estimate that 50% of people living with 
HIV are impaired on verbal fluency tasks. A meta-analytic review of verbal fluency 
impairments in HIV infection reported that impairments ranged from mild-to-
moderate in both letter and category fluency, and worsened with disease 
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progression (Iudicello et al., 2008). Furthermore, deficits in verbal fluency switching 
are uniquely predictive of self-reported declines in instrumental activities of daily 
living among older HIV-infected adults including medication and financial 
management (Heaton et al., 2004; Iudicello, Woods, et al., 2012; Woods, Morgan, 
Dawson, Cobb Scott, & Grant, 2006), a clear indication of the real-world implications 
of executive dysfunction.  
1.5.3.5. Visuo-spatial Function 
Research suggests that visuo-spatial cognitive abilities are relatively unaffected in 
HAND. Heaton et al. (1995) propose that this is because the associated regions of 
the brain – the occipital and parietal lobes - are some of the least affected by HIV 
virology.  
1.5.4. Impact of HAND on Daily Living  
Heaton et al. (2004) evaluated the ‘real-world’ impact of HAND in a group of 267 
people with HIV infection. Participants with HAND performed worse on all measures 
of everyday functioning than those without, and cognitive impairments on tests of 
executive function, learning and memory, attention, and verbal abilities most strongly 
predicted functional impairments. Impairments in memory and executive functioning 
may be particularly disabling due to their functional implications for occupational 
employment, domestic or household responsibilities, social functioning and health 
care management. Impairments in executive functioning may also lead to increased 
impulsivity, poor planning and abstract thinking, and aggression (Gilbert & Burgess, 
2008). 
More specifically, an overview of the literature suggests that cognitive impairments 
are associated with difficulties with medication adherence (Hinkin et al., 2002; Levine 
et al., 2005); driving (Marcotte et al., 2004); employment, mood, fatigue, and 
interpersonal relationships (Gorman, Foley, Ettenhofer, Hinkin, & van Gorp, 2009). In 
addition to this, HAND has also associated with increased mortality (Ellis et al., 1997; 
Sevigny et al., 2007; Vivithanaporn et al., 2010).  
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1.6. Social Cognition 
Social cognition refers to the range of cognitive mechanisms and processes that 
enable individuals to interact as social beings (Fiske & Taylor, 1991). Basic social 
interaction is essential for human survival, and as such, the effect of undetected 
impairment may potentially be very disabling and distressing for individuals and 
those in their social network (Saxe, Carey, & Kanwisher, 2004). 
1.6.1. Background to Social Cognition 
Social cognition is a relative new area of neuroscience, emerging from the literature 
of Evolutionary Psychology regarding the evolution of humans as a species 
equipped to function in social groups and Clinical Psychology research into disorders 
where impairments in social functioning are viewed as characteristic of the clinical 
presentation (e.g., ASC). That said, over the last two decades there has been 
growing research exploring social cognition in individuals with a diagnosis of 
schizophrenia (Green, Horan, & Lee, 2015), brain injury (Bibby & McDonald, 2005), 
the behavioural variant of FtD (Ruiz-Tagle, Musa, Lillo, & Slachevsky, 2015) and 
Huntingdon’s Disease (Bora, Velakoulis, & Walterfang, 2016). 
Historically, the neuroscience of social cognition has been dominated by conceptual 
framework of restrictive phrenology that links demarcated brain regions to 
underspecified social processes. Frith and Frith (2012) advocate for a break away 
from this reductive perspective, towards developing a mechanistic account of social 
processes. In view of this perspective, the authors explain that it is largely general 
mechanisms that enable our social processes.  
Using a leading theory among many cognitive psychologists and neuroscientists, 
Frith and Frith (2012) make the distinction between implicit processes and explicit 
processes in social cognition; those that are automatic and those that are controlled. 
Adolph (2009) elucidates; at an implicit level, one has swift automatic social 
processes, fraught with biases and stereotypes of which we are often unaware. At an 
explicit level, there is the ability to consciously and strategically set up our behaviour 
to contribute to towards complex social means. A review by Lieberman (2007) 
outlines the various properties attributed to implicit and explicit processing in this 
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context, and Heyes (2011) provides an exploration of the problems raised by this 
distinction. 
Frith and Frith (2012) outline a range of social processes which make up social 
cognition, including the perception and comprehension of biological status; the 
perception and comprehension of faces; the perception and comprehension of 
emotions; observational learning and copying; the attribution and tracking of others 
mental states; and, the ability to engage in reflective ‘meta cognitive’ discussion and 
thought processes. It is outside the scope of this study to comprehensively explore 
all of the social processes and underlying mechanisms which make up social 
cognition, and therefore, in keeping with the previous research (Ireland, 2011), the 
following discussion will focus on mentalising - the ability to attribute and keep track 
of the mental states of others.  
Mentalising enables humans to understand one another with a high degree of 
precision, and is made up of both implicit and explicit social processes, both 
supported, in part, by general cognitive mechanisms. The implicit processes are 
involved in perspective taking and tracking the intentional states of others, and are 
likely shared with other social non-human species. The explicit processes, in 
contrast, refer to the conscious differentiation of mental states between self and 
other: that is, the articulated awareness that others’ and one’s own mental states can 
differ. This ability, the authors suggest, is more likely to be unique to humans along 
with our ability for ‘meta-cognitive’ self-reflective conversation (Adolphs, 2009; Frith 
& Frith, 2012). 
Frith and Frith (2012) note that mentalising and ‘Theory of Mind’ (ToM) are often 
conflated in the literature, with mentalising often referred to as ‘having a ToM’. The 
concept of ToM refers to an individual’s ability to infer others’ mental states; it is 
commonly considered to be a multidimensional construct and a key theory in the 
field of social cognition (Kalbe et al., 2010). However, the authors distinguish 
between mentalising and ToM on the basis that the linguistic connotations of the 
phrase ‘theory of mind’ misleadingly implies conscious (i.e., explicit) processes only, 
thus obscuring the role of implicit processes. 
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1.6.2. Assessments of Social Cognition 
Historically, in both general and clinical populations, social cognition has most 
commonly been assessed using tests devised from the ToM paradigm (Baron-
Cohen, Leslie, & Frith, 1985).  
ToM tests can also be described as tests of explicit mentalising (Frith & Frith 2012). 
These assessments involve the attribution of a character’s beliefs; that is, they 
require participants to predict (and sometimes explain) behaviour based on a 
character’s mental state. There are a variety of ToM tests now available, with more 
advanced ToM tasks presenting more complex situations. 
As stated, difficulties with social communication are a key feature of ASC. A widely 
held theory which has been used to account for this is the idea that people with ASC 
have a deficit in ToM. This is based on the observation that sample groups of this 
nature have reliably been shown to perform more poorly on ToM tests than non-ASC 
controls (who are assumed to have no difficulty with social cognition). From this it is 
deduced that people with ASC struggle to see that other people’s behaviour is 
motivated by underlying mental states (the basis of the ToM hypothesis), and that 
ToM tests tap into the impaired cognitive mechanisms inherent in people with ASC 
that bring about their real-life wide-spread difficulties with social abilities.  
Begeer et al. (2010) compared the performance of people with ASC to a control 
group, on a novel test of ToM. The method of ToM assessment, in this study, 
involved using a ToM communication task which required real verbal interaction and 
thus ‘online’ processing of a social situation – markedly different to more traditional 
script- based tests of ToM. The authors hypothesised that the participants with ASC 
would show impaired performance relative to the controls, based on the 
aforementioned literature. However, the results found no such pattern, and the 
authors concluded that an absence of ToM deficits in verbal communicative 
interaction likely indicated an absence of systematically deficient ToM. A 
consideration of implicit and explicit processes of mentalising might also bare 
significance to these findings. Traditional ToM assessments typically assess explicit 
mentalising (Frith & Frith, 2012) and it is on these that the strength of the association 
between ‘ToM deficits’ and ASC is built (Frith & Frith, 2012; Yirmiya & Erel, 1998). 
However, the novel communication task used by Begeer et al. (2010) may have 
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involved different implicit and explicit processes, as well as underlying cognitive 
mechanisms, which may have influenced performance. Of note, although the ASC 
participants did not demonstrate deficit ToM, they did show a reduced tendency to 
use ‘mentalistic’ non-literal terms (e.g., affect-related words) to describe social 
narratives, than their non-ASC counterparts. So although there was a difference in 
communication styles which could be associated with social cognitive difficulties, it 
was not, in this instance, picked up by the ‘ToM’ test.  
This relates to a critique of the ToM paradigm, which argues that a problematic 
interpretive leap has been made between the observable behaviour (performance on 
tests) and the existence of a hidden inner world of the 'mind' and of assumed mental 
processes (Shanker, 2004). Indeed, critics of the ToM paradigm have argued that 
the very idea that people with ASC have ToM deficits is an article of faith, contesting 
the validity and reliability of ToM. One such point concerns the discussion around 
what is a ‘normal’ score on the Reading the Mind in the Eyes Test (RMET), following 
variations in the literature (Baron-Cohen et al., 2001; Fine, 2011).  Additionally, Fine 
(2011) highlights the impact that implicit cognitive biases can have on performance 
on ToM tasks: detrimentally affecting performance leading to misattribution of 
‘impairment’ in certain groups (i.e., stereotype bias and gender).  
Although substantial advancements have been made in determining the neural 
underpinnings of social cognition in recent years (Saxe, 2006), there remains a 
dearth in the development of assessment tools for social cognitive processes. These 
criticisms of ToM support a rationale for including multiple forms of assessment to 
allow for the cross-referencing of test outcomes. 
1.6.2.1. Affective and Cognitive Theory of Mind 
ToM has been conceptualised as comprising of two separate subcomponents; 
‘cognitive’ and ‘affective’ (Stone et al., 1998). Cognitive ToM concerns the ability to 
use abstract reasoning to understand another person’s mental state, and affective 
ToM concerns the social-perceptual understanding of non-verbal emotional 
processing. In support of this differentiation, various studies have reported that 
individuals are differentially impaired on tests of cognitive and affective components 
of ToM. Torralva et al. (2015) found that patients with FtD were more impaired on 
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tests of affective ToM, than cognitive ToM, in the early stages of the disease. 
Similarly, both Ireland (2011) and Homer et al. (2013) reported that people with HIV 
infection demonstrated greater trends of impairment on a test of affective ToM (as 
assessed using the RMET) than on a test of cognitive ToM; and that performance on 
both tests was independent of each other.  
1.6.2.2. Theory of Mind and Executive Function 
The ‘domain-general’ hypothesis of ToM is the widely held view that ToM skills rely 
on executive functioning abilities in order to operate. This theory argues that 
impairments in ToM (and social cognition more generally) occur due to underlying 
impairments in executive functioning, for example, response inhibition  (Henry, 
Phillips, Crawford, Ietswaart, & Summers, 2006). In support of this hypothesis, a 
study by Hughes and Russell (1993) - which looked at social dysfunction in children 
with ASC - reported that subjects social cognition impairments were secondary to a 
more general deficit in executive function, rather than a specific deficit in social 
cognition.  
However, an alternative theory is that ToM is domain specific (Stone & Gerrans, 
2006). This view posits that aspects of social cognition and executive functioning, 
whilst both associated with frontostriatal brain regions, may have distinct neural 
pathways which can be impaired without causing injury to the other. This is 
supported by several studies from the field of FtD - a spectrum of degenerative 
conditions associated with focal atrophy of the frontal lobes - which has a 
behavioural variant characterized by progressive deterioration in social function 
(Rascovsky et al., 2011). See Harciarek and Jodzio (2005) for a review in this area. 
In regards to HAND, both Ireland (2011) and Homer et al. (2013) reported that 
subjects demonstrated impaired performance on ToM tests, independent to 
impairments in executive function. Finally, Roca et al. (2010) argue that there is 
something specific to ToM skills for which executive functions do not account, and 
they advocate for the separation of ToM and executive function; emphasising the 
importance of assessing ToM independently to other cognitive domains.  
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1.6.3. Emotional Perspective Taking: Empathy 
Also conceptualised as emotional perspective taking (Adolphs, 2009; Frith & Frith, 
2012), Empathy has been identified as one of the most important mechanisms which 
contribute towards overall social cognition (Blakemore & Frith, 2004).  
Until recently, there has not been a general consensus as to its definition. Existing 
descriptions have tended towards a view of empathy as involving either the 
recognition of emotion, the experience of it, or both (Batson, 2009; Blair, 2005; 
Decety & Lamm, 2006; Elliott, Bohart, Watson, & Greenberg, 2011; Gini, Albiero, 
Benelli, & Altoè, 2007; Lawrence, Shaw, Baker, Baron-Cohen, & David, 2004; 
Spinella, 2005) 
However, Reniers et al. (2011) propose that instead of being at odds with one 
another, these elements of empathy are neurocognitive processes which, although 
partly separate, are encompassed within the wider concept of empathy. The authors 
pull together and synthesise much of the dominant literature on empathy, and 
propose a model which defines empathy as a multifaceted construct that can be 
delineated into two core parts, cognitive empathy and affective empathy. Cognitive 
empathy concerns one’s ability to construct a working model of the emotional states 
of others, whilst affective empathy is the ability to be sensitive to and vicariously 
experience the feelings of others. Distinguishing cognitive empathy from TOM, 
Reniers et al. (2011) explains that optimal “cognitive empathic skills are likely to draw 
on many of the same underlying process that enable ToM, but, cognitive empathy is 
concerned with the attribution of emotions as opposed to cognitions, and as such the 
two constructs are potentially dissociable” (Reniers et al., 2011, p. 85). 
Frith and Frith (2012) note that empathy, even though likely underwritten by a 
general mechanism of association learning, has some claim to be a specifically 
social process, having social content and being solely in the service of social 
functionality. 
1.6.4. Prefrontal Cortex and Social Cognition  
In a review on the neurobiology of social cognition, Adolphs (2009) notes that our 
neural mechanisms have evolved to allow for social interaction, and specialization 
may be evident at the level of neural processing. The prefrontal cortical regions of 
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the brain appear to be the areas that have expanded the most in human evolution 
(Holloway, 2002; Semendeferi, Armstrong, Schleicher, Zilles, & Van Hoesen, 2001) 
and are involved in uniquely human capacities, including numerous complex abilities 
required to negotiate the social word in which we live (Stuss & Levine, 2002). In line 
with technological advances, neuroimaging studies are beginning to identify 
structures that play a key role in guiding social behaviours and communication, 
including (but not limited to) regions of the prefrontal context (PFC). Adolphs (1999, 
2009) cautions that many questions remain about the modularity or domain-
specificity social cognition, its intersection with emotion and with communication, and 
about the methods best suited for its investigation.  
Regions in the PFC have been implicated in social cognition dating back to the case 
of Phineas Gage (Damasio, 1994) which associated damage to the PFC with an 
impaired ability to plan and execute future activities; a reduced capacity to respond 
to punishment; increased inappropriate social manners, and an outward lack of 
concern for others, all alongside otherwise intact and normal intellectual functioning. 
Since then, existing studies in neuroscience offer various examples of where 
impairment to PFC is associated with impaired social ability. The medial prefrontal 
cortex has been linked to ToM abilities in a number of imaging studies (see Adolph, 
1999 for a review of 17 studies) and, in lesion studies, damage to orbitofrontal cortex 
has been linked with impaired ability to recognize a violation of social norms in a 
social narrative (Bibby & McDonald, 2005; Stone et al., 1998).  Furthermore, ASC 
too have been shown to correlate highly with structural abnormalities in the PFC  
(Happe & Frith, 1996).  
Huntingdons and ftD are both degenerative neurological conditions which cause 
focal atrophy in the PFC. Studies from both conditions report progressive 
deterioration in social abilities and difficulty maintaining interpersonal relationships in 
line with neural damage and alteration (Kipps & Hodges, 2006; Rascovsky et al., 
2011; Snowden et al., 2003). 
1.6.5. Neural Correlates of Explicit Mentalising 
Frith and Frith (2012) state that the cognitive mechanism for mentalising is carried by 
a network of frontal and temporo‐parietal regions of the brain. Current research on 
the neural correlates of ToM (i.e., explicit mentalising), suggest that the act of 
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making inferences about mental states engages various regions in the PFC (Apperly, 
Samson, Chiavarino, Bickerton, & Humphreys, 2007; Koster-Hale & Saxe, 2013; 
Lieberman, 2014). The region of the PFC most commonly associated with ToM 
abilities appears to be the dorsomedial PFC (Schurz, Radua, Aichhorn, Richlan, & 
Perner, 2014), which is linked with perspective taking abilities and direct and 
reflected self-knowledge (Ochsner & Gross, 2005).  
Despite a large body of literature implicating the dorsomedial PFC in ToM tasks, little 
is known about the neural underpinnings of the implicit mentalising (Frith & Frith, 
2012). 
With regards to the aforementioned distinction between cognitive and affective ToM, 
Shamay-Tsoory and Aharon-Peretz  (2007) found that the dorsolateral PFC is linked 
to the 'cognitive' component of ToM whilst the ventromedial PFC has been 
associated with the 'affective' aspects of ToM. Kalbe et al. (2010) also investigated 
the possible neural correlates of affective and cognitive ToM in a study with healthy 
male subjects. The authors reported evidence for the functional independence of 
cognitive from affective ToM, and identified the possible role of the right dorsolateral 
PFC in cognitive ToM.  
1.6.6. Social Cognition and Context  
Social Cognition is sensitive to context, and the brain regions involved in social 
cognition are modulated in their activation by social context and volitional regulation 
(Adolphs, 2009). An example of how contextual information affects social information 
processing is shown in a study by Kim et al. (2004), which reported that information 
about faces was processed differently depending on context. A surprised face was 
interpreted as looking either afraid or happy, depending on the preceding priming 
sentence. Interpretation of context and degree of individual control varies between 
individuals and substantial differences exist in many of the processes and structures 
discussed above (Adolphs, 2009). 
1.7. Social Cognition in HAND 
Mild decline in social functioning is included in the classification criteria for ANI but 
impairment to social cognition is not explicitly defined as a component in the 
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neuropsychological profile of HAND (Andrea Antinori, Arendt, Grant, Letendre, & 
Muñoz-Moreno, 2013).  
A small study by Ireland (2011) reported that participants (N=16) with HIV infection 
showed social cognition deficits which existed separately to that of other patterns of 
cognitive impairment including executive function performance. Assessment of social 
cognition was achieved using two tests of ToM, representing both cognitive ToM and 
affective ToM. Participants appeared more impaired on a test of ‘cognitive ToM’ 
(Strange Stories Task; SST) than the ‘affective ToM’ (RMET).  
These findings were supported by the results of a study by Homer et al. (2013) who 
explored the impact of methamphetamine-use and HIV infection on performance on 
two measures of ToM, (the RMET and a Faux Pax Test) and a test of executive 
function (Stroop Colour and Word Test). The authors found that HIV infection was 
associated with impaired performance on the RMET, and methamphetamine-use 
was associated with impaired performance on the Faux Pas Task. The different 
performance across the two ToM tests was said to reflect the different underlying 
cognitive mechanisms required; in contrast to the RMET’s basic “bottom-up” 
perceptual process, the Faux Pax Test may be rely on “top-down” script-based 
processing, where successful performance requires access to ‘offline’ overlearning 
knowledge about social norms and conventions rather than ‘online’ in-the-moment 
social processing (Homer et al., 2013). Thus, the authors concluded, certain 
everyday social communications may be dependent on pre-existing rote knowledge 
of social behaviour, and require little active social cognition. In view of this, 
individuals with HIV might rely on overlearning knowledge to compensate for 
impairment in ‘online’ mentalising. This view is supported by the results of a study by 
Porter, Coltheart and Langdon (M. A. Porter, Coltheart, & Langdon, 2008), who 
explored social cognition in individuals with Williams Syndrome, and reported that 
the subject demonstrated impaired performance on ToM tasks that did not involve 
social scripts, but no such deficits in similar tasks that did involve social scripts. 
1.8. Rationale  
As people with HIV in the UK continue to live longer and healthier lives, so the 
longevity and complexity of HAND continues to increase. In the context of the 
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emerging chronicity of HAND in the post-cART era, it remains the case that the 
cause and temporal progression of HAND remain unclear, and no cART or other 
therapy has shown unequivocal benefits for treating or preventing HAND. What 
remains, therefore, are the disabling effects of cognitive impairment for people with 
HIV in everyday life, including pervasive impact on quality of life, and potential 
compromise of treatment adherence impacting long-term virological control and 
HAND phenomenology. In this context, Clinical Psychology has a clear role in 
developing the wider understanding of the neurocognitive consequences of living 
with HAND, which in the current study, focuses on exploring the emotional and 
behavioural sequelae of HAND using the theory of social cognition. 
The frontal lobe areas of the brain are implicated in HIV CNS infection, and, as 
reviewed above, there is a vast literature from non-HIV clinical populations detailing 
the relationship between PFC injury and social dysfunction; particularly so with 
explicit mentalising and emotion recognition (Amodio & Frith 2006).  These skills 
may be critical to social communication (Saxe, 2006) and a key aspect of everyday 
social cognition and associated impairments may be disabling for those concerned. 
Despite this, there is a relative dearth of research into the profile of social cognition 
impairments in HAND. In the last six years, studies by Homer et al. (2013) and 
Ireland (2011) both reported trends in impaired explicit mentalising and emotion 
recognition skills in people with HAND, independent to executive dysfunction or 
global cognitive decline. These findings suggest that social cognitive impairments 
may be characteristic of HAND, and although these results remain tentative and 
based on small numbers, they highlight the need for further research in order to 
explore, replicate and extend findings, and move closer towards conclusions 
generalizable to the clinical population. In view of this, the current study aimed to 
build upon existing research to explore the profile of social cognition impairments in 
the neuropsychological profile of HAND.   
1.9. Research Questions 
The following research questions were devised based on the findings and 
recommendations of Irelands (2011) study in which specific recommendations were 
made with regards to; the continued exploration of social cognition impairments 
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within a diverse HIV-positive adult cohort; the continued focus on specific ‘areas’ of 
social cognition with the view to remain within the same constructs within social 
cognition; and, the selection and application of different test materials for the 
assessment of social cognition in order to minimise confounding variables and 
improve ecological validity. Irelands (2011) recommendations for test materials are 
detailed alongside the rationale for each individual test selection in the ‘Method’ 
section.  
The research questions are as follows:  
1) What is the cognitive profile (areas of strength versus weakness) of social 
cognition in HAND?  Does HAND affect, or differentially affect, for example 
a. cognitive-linguistic function e.g., comprehension of non-literal language 
b. emotion recognition e.g., of facial expression 
c. empathy e.g., capacity to engage with other persons. 
2) Is there a correlation between stage of HIV illness and social cognitive 
functioning? 
This study will employ a number of neuropsychological tests and questionnaires in 
order to explore the research objectives. Utility of such tests rests on the underlying 
assumption that visible and measurable performance echoes something about the 
invisible and unmeasurable internal biological functioning of the individual in their 
context. It is important to note that there are many variables which may affect 
performance on tests, separate to biological status. Where confounding variables 
cannot be controlled, they will be closely monitored and limitations of this approach 
will be held in mind and discussed in the results.  
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2. METHOD 
2.1. Epistemology 
Philosophical assumptions regarding ontology and epistemology are central to all 
scientific enquiry. Ontology represents the philosophy of reality; our 
conceptualisation of the world around us (Bunge, 1974); whereas epistemology 
denotes the philosophy of knowledge; our beliefs and assumptions about how we 
come to know about the world around us; including the scope, methods and 
limitations of such knowledge. Barker, Pistrang, and Elliott (2003) note the 
importance for researchers to acknowledge the philosophical context in which their 
data is obtained, as these assumptions underpin and guide the methodological 
design and possible data analyses. In view of this, a brief summary of the 
philosophical position taken by the researcher is provided below, although it remains 
outside the scope of this discussion to provide a historical review of - or current 
tensions within - the field.  
The chief researcher identified as holding a critical realist perspective. Fleetwood 
(2005) explains that critical realism is a meta-theory for social sciences; concerned 
with the philosophy of science, ontology, epistemology, and aetiology, together with 
ideas about what constitutes an explanation, a prediction, and what the objectives of 
social science ought to be. This paradigm is one which posits that the world is real, 
and therefore open to scientific study, whilst remaining critical of our ability to know 
any such reality with any certainty due to fallibility and errors in observation and the 
inherent innumerable biases of the scientist.  
Whilst these research questions might, typically, be associated with a more 
traditionally positivist epistemological paradigm, the choice to explicitly adopt a 
critical realist stance was informed by the researcher’s desire to remain aware of the 
socially constructed nature of the concepts discussed so as to avoid reinforcing 
essentialist discourse. This awareness includes, but is not limited to, the artificial and 
evolving nature of the current conceptualisations of ‘core neuropsychological 
domains and ‘social cognition’.  Further, Sontag (2002) discusses how the social 
construction of meaning attributed to diseases such as HIV-infection enables a 
consideration of how these theories have evolved over time in an otherwise invisible 
socio-political context, allowing, then, for an acknowledgment of how the uptake of 
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these constructions and metaphors into essentialist discourses can, in themselves, 
cause suffering for people with HIV, altogether separate to the impact of the 
biological illness.  
Critical realism advocates for the use of multiple measures of assessment and 
analysis in order to learn as much about our reality as possible. In view of this, the 
current study included a clinical interview and a self-report measure as part of the 
information gathered alongside the neurocognitive assessments, and employed a bi-
modal method of data analysis (group-level statistical analysis and individual-level 
case analysis) to, as best possible within the study resources, learn as much about 
the research questions as possible.  
The present-day conceptualisations of cognitive impairment and social cognition will 
continue to evolve and change alongside developments in our understanding of 
neurocognitive domains and HIV-infection. However, whilst it is essential to remain 
critical of the subject matter and aware of the fragility of ‘knowledge’, in the 
immediate context, these constructs and theories offer a limited, yet meaningful and 
pragmatic apparatus with which to advance exploratory research. This kind of 
methodology in social sciences is one which is increasingly being recognised as 
befitting of a critical realist perspective (McEvoy, 2006; Olsen & Morgan, 2005). 
2.2. Regulatory Ethical Approval 
Study registration and ethical approval were first secured from the host University 
(see Appendix B - C) and from the NHS ethics committee (see Appendix D - E). 
Permission to conduct the study and to recruit from each NHS site was sought and 
obtained from each Trusts’ internal Research and Development Team (Appendix F- 
G). Additionally, the Directorate covering one recruitment site required an Internal 
Scientific Peer Review authorisation, for which approval was sought and gained 
(Appendix H - J). All processes were completed prior to recruitment commencing.  
2.3. Inclusion and Exclusion Criteria  
2.3.1. Approach to Developing Inclusion Criteria  
A small core set of essential inclusion criteria were developed for the study, followed 
by a list of broader considerations required to assess participant suitability; in this 
35 
 
way, a flexible approach was taken. Although strict exclusion criteria are often 
imposed in neurocognitive research (e.g., excluding co-morbidities), that approach in 
this instance was deemed impractical based on a number of factors, including the 
guidance from senior clinicians at each recruitment site, who were able to draw upon 
their expert understanding of the clinical population as well as their experience of 
supervising similar such studies. Additionally, previous studies which have attempted 
to recruit only ‘pure’ HAND (by excluding co-morbidities) have been required to relax 
exclusion criteria in order to recruit adequate samples (Ireland, 2011; Johal, 2014). 
Thus, given the chronic and episodic nature of HIV and its highly prevalent 
associated co-morbidities (Heaton et al., 1995), a flexible approach was advised. 
This strategy is in keeping with advice in the literature, which cautions against 
excluding common HIV-related co-morbidities in HAND research to avoid research 
samples becoming unrepresentative of the population (Robertson, Liner, & Heaton, 
2009) 
Assessment of a patient’s suitability for inclusion was done on a case-by-case basis 
by the researcher in collaboration with the research supervisor, referring clinician, 
and if necessary, senior clinician and medical consultant.  
2.3.2. Core Inclusion Criteria  
The primary inclusion criteria were; a diagnosis of HIV infection; fluent English 
language comprehension and expressive abilities; older than 18 years old. These 
and further factors influencing eligibility are outlined below. 
2.3.3. Language Facility   
Participants were required to understand written and spoken English fluently, but not 
required to have English as a first-language. Although first-language English status 
would have been preferable given the language components of some of the test 
materials, the cultural-linguistic diversity of the target population made this 
unfeasible.  
Where potential participants were referred directly to the researcher, their degree of 
English language facility was assessed by the referrer who was well placed to 
identify language ability. Where potential participants were identified from a waiting 
list, language facility was identified through liaising with the site consultant. Suitability 
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was checked again at first contact and assessed during testing; participant’s 
performance on a test of reading individual words (the Wechsler Test of Adult 
Reading; WTAR) which gave an indication of language facility during the test battery.  
2.3.4. HIV and HAND Diagnosis  
A diagnosis of HIV was required; however, a diagnosis of HAND was not necessary 
given that ANI - the most common form of HAND – is ‘asymptomatic’ and therefore 
likely to be under-diagnosed in services were neuropsychology testing is not 
routinely offered. People with ANI present with mild neurocognitive difficulties which, 
although clinically determinable, are thought to have a minimal impact on their 
everyday functioning. Given that neither of the two recruitment sites operated routine 
neuropsychological assessments, limiting the recruitment criteria to only include 
those with a pre-existing diagnosis of HAND would serve to restrict the pool of 
potential participants to those with more pronounced impairments. Furthermore, it 
could be confidently assumed that all potential participants would have explicit 
neurocognitive symptom or complaint, as participants were identified from a waiting 
list for neurocognitive assessment or referred directly by clinicians based upon an 
existing clinical need. 
HAND status was noted from participants’ medical files but not used for exclusion 
purposes as the variability would inform the profiling process. HAND status was 
classified as belonging to one of four levels; Impairment not otherwise specified (I-
NOS), ANI, MCD, and HAD. 
2.3.5. Medical Co-morbidities  
Within the NHS context, all potential participants attended routine health 
examinations which screened for HIV-related illnesses which might also cause CNS 
complaints. Following discussions with the site consultant physician, it was noted 
that Hepatitis B and C are frequently seen co-morbid infections. Although these can 
impact global cognitive performance, it was agreed that relevant people would be 
invited to participate as long as they were under treatment and maintaining usual 
levels of daily functioning. Medical conditions such as Stroke, Dementia and 
Encephalopathy are also associated with HIV infection, and participants were 
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considered suitable for participation following an assessment of type, severity and 
capacity to consent. 
CNS tumours, metabolic diseases, and delirium are frequently seen in individuals 
where untreated or resistant HIV infection is present. However, no individuals were 
encountered who presented with these conditions. This was consistent with the 
outpatient demographic, where a high proportion of patients are cART-adherent with 
undetectable viral loads and well managed immune strength.  
2.3.6. Substance Use 
The literature states that substance use is highly prevalent among people living with 
HIV and AIDS (Colfax & Guzman, 2006; Gonzalez, Barinas, & Cleirigh, 2011; 
Williams et al., 2010). This finding was consistent with reports from senior clinicians 
at both recruitment sites who reported common use of ‘club drugs’ (e.g., MDMA, 
gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine) amongst a large sub-
section of registered patients. However, no such history presented in the recruitment 
phase. 
It was agreed that potential participants would not be excluded from participant 
based on a history of substance use unless there was evidence of associated brain 
damage (e.g., Korsakoffs dementia). However, individuals with long-term current and 
multiple substance use (e.g., crack-cocaine and heroin) were not invited to 
participate do to the impact that this would have had on baseline cognitive 
functioning (Casaletto et al., 2016; M. Lezak, Howieson, Bigler, & Tranel, 2012).  
2.3.7. Psychological Co-morbidities  
There is a higher than average prevalence of anxiety and depression for individuals 
with HIV. Both conditions, and their associated pharmacological treatments, are 
shown to influence cognition and performance on neuropsychological testing in non-
clinical populations (Ferreri, Lapp, & Petetti, 2011; Goldstein & Mcneil, 2003; R. J. 
Porter, Gallagher, Thompson, & Young, 2003) with anxiety linked to distraction and 
off-task rumination, depression linked with low motivation and effort, and 
pharmacological treatment having an impact of cognitive performance (M. Lezak et 
al., 2012).  
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However, the literature regarding the impact of anxiety and depression on 
neurocognitive test performance of people with HIV reports conflicting findings. 
Some studies have reported that depression and/or anxiety significantly confound 
performance on cognitive tests; for example, Rourke et al. (1999) reported that 
depressive symptoms account for variation in test performance. Additionally, in a 
study by Castellon et al. (2006), low motivation (a key factor in depression) was 
associated with impaired verbal memory, executive functioning, and motor 
performance; cognitive domains which also feature as key areas of impairment in 
those with HIV.   
In contrast, others studies report no such relationship (Carter et al., 2003), or report 
that depression affects subjective complaints of cognitive impairment but not 
objectively assessed cognitive impairment itself (Carter et al., 2003; Millikin et al., 
2003). This inconsistency is, in part, likely influenced by variability in test materials, 
assessment criteria and sample groups, and further complicated by the nature of 
both anxiety and depression as being multi-dimensional constructions (Castellon et 
al., 2006). Nonetheless, neuropsychological testing for HAND routinely includes 
assessment of mood and anxiety to allow for some standardised consideration of the 
extent to which mood state may be a confounding influence on test performance.  
In recognition of the elevated prevalence of psychological co-morbidity in the target 
population, and acknowledging the guidelines of Gibbie et al. (2006) who advise that 
an improvement in neurocognitive test scores can occur in those with HIV who have 
been treated for their low mood, it was agreed that potential participants would not 
be excluded from the study if they presented with mild-moderate anxiety. Status 
would be assessed at several points, including; the clinical judgement of referring 
clinicians; the researcher; and, the Hospital Anxiety and Depression Scale (HADS) at 
time of testing, to assess severity and ‘caseness’ of anxiety and depression. 
Similarly, any potential participants with a ‘bi-polar’ or ‘psychosis’-related diagnosis 
whose experiences were well managed would also be considered appropriate, and 
only excluded in the event of acute or untreated symptomology due the inseparable 
and acute confounding influences of such experiences on test performance (M. 
Lezak et al., 2012). 
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2.3.8. Learning Disabilities 
Gillberg (2003) reports that learning disabilities affect 1-2.5% of the general 
population in the Western world, and a person with a learning disability may have 
difficulty learning and managing daily living skills due to impaired cognitive 
processing before the age of 18 years, resulting in an IQ score below 70. The 
neurocognitive tests and associated normative data used in the current study are 
inappropriate for use with individuals who have a severe baseline cognitive and 
functional impairment (Randolph, Tierney, Mohr, & Chase, 1998). For this reason, it 
was agreed that patients who met this criteria would not be invited to participate.  
2.3.9. Capacity to Consent 
As this study sought to recruit individuals with some degree of cognitive impairment, 
each potential participant’s capacity to consent to considered. Only patients with 
capacity to make the decision to take part in the study and provide consent were 
contacted and invited to participate in the study. See the ‘Ethical Issues’ section for 
further considerations regarding capacity, consent, and HIV-infection. 
2.4. Recruitment Procedure 
Participants were recruited from two multi-disciplinary HIV outpatient services in 
London.  An NHS clinical sample was sought as the organisational context proffered 
specialist healthcare services in which people who met the inclusion criteria could be 
located, alongside available and up-to-date medical health information necessary in 
order to determine participant suitability and ensure ethical participation. Recruiting 
from NHS services also ensured that the sample would be as representative of the 
target population as possible. This research is in keeping with the NHS ethos and 
constitutional commitment to continuous improvement (NHS constitution for England, 
2012); any pertinent results from this study might serve to inform the direction of 
future research, contributing knowledge with which to inform the development of 
evidence-based services. 
The chief investigator informed the staff teams at each site about the study, by 
presenting the study rationale and recruitment procedure at their multi-disciplinary 
clinical team meetings. After this point, due to variability in service provision, a 
different recruitment strategy was required for each.  
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As Site A did not have an internal neuropsychology service, senior on-site clinicians 
invited suitable participants to the study and those who consented were referred 
directly to the researcher and on-site supervisor.  
Site B had an internal neuropsychology assessment service as part of their Clinical 
Psychology service provision. Therefore, suitable participants were identified from a 
patient waiting list for neurocognitive assessments. 
At both sites, the researcher checked the referred participant’s medical files to 
identify their contact preferences (in line with strict Trust confidentiality protocols). 
Phone and email contact was then established with referred participants to assess 
suitability, provide verbal information about the study, obtain consent, and arrange 
an assessment slot. Where suitability was unclear, supervision was sought and the 
appropriate actions were decided, before the patient was invited to participate.  
2.5. Assessment Procedure  
All participants were invited to attend a two hour assessment appointment at their 
registered NHS service, where they were seen in a private clinic room. Information 
about the study was provided to the participant in writing, using the Participant 
Information Sheet (see Appendix K). Once verbal and written consent was gained 
(see Appendix L), a brief clinical interview established educational history, 
occupational status, English ability, mood and cognitive complaints. Following this, 
the test battery was administered.  
The WTAR was administered first, followed by the UK version of the Repeatable 
Battery for the Assessment of Neuropsychological Status (RBANS), and finally the 
social cognition tests. A 30-minute break midway was offered in order to minimise 
the effects of fatigue. If declined, participants were monitored for signs of fatigue and 
reminded to stop if necessary. 
Once testing had finished, participants were given the opportunity to reflect on the 
testing process and offered verbal debriefing. They were informed that they would 
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receive a full report within the month, which, with their consent, would be shared with 
the team consultant for the purposes of informing future care.   
The Mind Exchange Working Group Guidelines  (2013) advise that assessments 
should be conducted at times when the patient is not experiencing unnecessary 
fatigue, or severely low mood, and when medical status is generally stable. The 
procedure was devised with these factors in mind.  
All participants were offered a direct or phone-based follow-up appointment to 
receive feedback and have the opportunity for their neuropsychological rehabilitation 
recommendations (if required) explained. 
2.6. Design  
A cross-sectional correlation design and an ‘Individual Profile Analysis’ were both 
employed to address the research questions, as together they enabled a detailed 
and descriptive exploration of a given number of variables, within a given time frame, 
within a representative group.  This research design was deemed the best fit for the 
exploratory aims of the study; to observe the differences between the variables of 
interest within a sample of individuals with HIV and allow for a comparison to 
published normative data. The variables of interest were social cognition and 
executive function and their relationship to general cognitive functioning in a group of 
individuals with HIV with varying levels of cognitive impairment.  
Since no data was to be manipulated, nor any trials or interventions offered, no 
control group was considered necessary. Although the inclusion of a comparator 
group may have enhanced the breadth of the study and the options of statistical data 
analyses, the resources required to operationalise and implement this 
recommendation were outside of the scope of this study due to the availability of 
time and resources.  
2.6.1. Analysis 
Participants’ raw scores for each neurocognitive subtest were converted into scaled 
scores (mean value of 10, standard deviation of 3) using published norms in test 
manuals. Consequent analysis was conducted using IBM SPSS Statistics 22.  
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As stated above, an Individual Profile Analysis was also included. Described as the 
“mainstay of cognitive neuropsychology” (Towgood, Meuwese, Gilbert, Turner, & 
Burgess, 2009, p. 11); this approach focuses on differences within rather than across 
individuals, with each individual effectively serving as their own control. In keeping 
with the exploratory nature of present study, this type of analysis is particularly suited 
to the study of populations with heterogeneous deficits, and allows for an 
examination of factors that may be missed at group-level analysis.  
2.6.2. Sample Size 
The sought after sample size was guided by methodology employed in similar 
exploratory studies of neurological impairments; neuropsychological research 
frequently involves a small sample size, and this observation is consistent with the 
numbers (i.e., sixteen participants) recruited for similar research projects which have 
been conducted with individuals with HIV (Ireland, 2011; Johal, 2014). 
As the research analysis was to focus on size of effect - which is considered 
relatively independent of sample size (Clark-Carter, 1999) a power calculation was 
not considered appropriate.  However, efforts to obtain as large a sample as possible 
were made in acknowledgement that the power and validity of research increases 
with sample size. 
2.7. Test Materials 
A neuropsychological test battery was developed to measure social cognition and 
core cognitive domains (i.e., executive function, learning and memory, attention, 
visuo-perception, and language). In line with the research questions; this enabled a 
comparison of cognitive function across key (executive function and social cognition) 
and core (see above) domains, to ensure that any deficits in social cognition were 
not secondary to global or specific decline or language facility. The selected tests are 
discussed below, and for clarity presented in a table in Appendix M. 
The RBANS UK version (Randolph et al., 1998) was used to assess attention, 
information processing speed, learning and memory, verbal function, and visuo-
spatial function. There are several standardised neuropsychological test materials 
that can be used to assess for deficits in these areas and it is possible, for example, 
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to use various combinations of the Wechsler Adult Intelligence Scale (WAIS; 
Pearson, 2008) and Wechsler Memory Scale (WMS; Wechsler, 1997) to these 
means (M. Lezak et al., 2012). However, The RBANS was chosen for its best-fit with 
the study design. The RBANs has reported reliability and utility when working with 
neurological injury or disease (Hodges, 2007); assessing neurological impairment in 
individuals aged 20 to 89 years old, including deficits in HIV associated cognitive 
impairment, as well as profiles symptomatic of other co-morbid diseases and 
syndromes (Hebben & Milberg, 2009). The relative brevity of the RBANS, in 
comparison to other test batteries, enabled the assessment to be conducted in a 
one-off appointment, facilitating the overall reduction of the burden on the participant.  
The RBANS test gives information about cognitive functioning in the following five 
areas; Immediate Memory, Delayed Memory, Visuo-spatial Function, Language and 
Attention, based on the administration of co-normed 12 subtests. Normative data is 
based on a sample of 540 American participants between the ages of 18 to 89, and 
is published in the test manual. Information on the gender of participants is not 
provided, however data on ethnicity is included: 81% of the sample were White 
American, 13% African Americans, and 7% Hispanic Americans.  
As recommended by Lezak et al. (2004), the RBANS was supplemented with 
additional procedures. To provide a more thorough assessment of executive 
function, the Verbal Fluency from the Delis-Kaplan Executive Function System 
(DKEFS)  set was included, as well as The Halstead Reitan version of the Trial 
Making Test; Part B (Reitan, 1955). To improve assessment of working memory, the 
Digit Span Backwards’ test was included (to complement existing Digit Span 
Forward). To improve assessment of information processing speed, the Trail Making 
Test (Part A) was also included.  
The development of this battery was consistent with the Mind Exchange Working 
Group Guidelines (2013) which advise that comprehensive neuropsychological 
testing for neuropsychological impairment in people with HIV should include a test 
battery of at least five neurocognitive domains, including attention/working  memory, 
speed of information processing, executive  function, verbal/language, 
learning/recall, and motor skills.  Testing should be done using standard and 
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validated  instruments for detection of HAND, and administered and interpreted by an 
appropriately trained professional.  
2.7.1. Assessment of Premorbid Functioning 
The WTAR (Wechsler, 2001) was used as one estimate of pre-morbid cognitive 
function. The ability to read words is believed to be resistant to cognitive decline until 
later stages of disease progression, and therefore performance is taken as 
representative of an individual’s optimal level of functioning and well as English 
language facility (Strauss, Sherman, & Spreen, 2006). The test requires participants 
to read aloud a list of fifty words with atypical grapheme-phoneme relationships 
which require irregular pronunciations. This unfamiliar quality reduces the likelihood 
of the participant speaking the word correctly based on a generalisation of common 
sound-letter language rules, and instead requires them to rely on previous learning 
of the words. Participants are scored on a pass or fail criteria according to the 
number of words read correctly. These scores are then compared to normative data 
to provide an index of function.  
However, since the WTAR assumes a ‘normal’ development of English reading skills 
prior to cognitive decline, it offers a less valid estimate of optimal functioning for 
speakers of English as a second language. In such instances, alternative methods of 
assessing pre-morbid ability are recommended. One such method is the ‘best 
performance’ approach which looks at the distribution and frequency of the best 
scores within the subjects own cognitive profile in order to determine optimal level of 
cognitive functioning (M. Lezak et al., 2012). In view of this, in addition to the WTAR, 
pre-morbid ability was also estimated using ‘best performance’ and educational 
attainment (as measured by total years of education).  
Thus, a dual approach was taken to the assessment of pre-morbid ability; 
participants were compared to both the normative population (i.e., WTAR norms) as 
well as compared to themselves (i.e., best performance score and educational 
achievement). 
2.7.2. Assessment of Attention and Information Processing Speed  
The RBANS Digit Span and Coding subtests were used to assess attention. The 
Digit Span test requires participants to to repeat strings of numbers, which increase 
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in length as the test progresses. The Coding test involves scanning a sequence of 
symbols and completing numbers according to a corresponding shape given in an 
initial coding key, under timed conditions. 
The Trail Making Part A (Reitan, 1955) was used to assess Information Processing 
Speed. This test pairs with the Trail making Part B test for an assessment of the 
task-set switching part of executive functioning. 
2.7.3. Assessment of Learning and Memory  
2.7.3.1. Verbal Learning and Memory 
The RBANS List Learning and Story Learning provided an assessment of verbal 
learning. In the List Learning subtest, participants were verbally presented with a list 
of 10 unrelated words and asked to immediately repeat back as many as they could 
remember; this was repeated across four trials. In the Story Learning subtest, 
participants were verbally presented with a short story, comprising of 12 pre-defined 
units of information, and asked to repeat as many details as they could remember, 
using the same language; this task was repeated for two trials. 
The RBANS List Recall and Story Recall provided an assessment of delayed 
memory. After a 20-minute delay following administration of the List Learning and 
Story Learning subtests, participants were asked to recall words/story narrative from 
each task to the best of their ability. The additional RBANS Story and List 
Recognition tasks assessed recognition memory.  
2.7.3.2. Visuo-spatial Learning and Memory 
The RBANs Figure Copy and Figure Recall subtests assessed visuo-spatial learning 
and memory. Participants were required to redraw the figure they had previously 
seen and copied for the Figure Copy test, after a 20 minute delay. 
2.7.4. Assessment of Verbal Function  
The RBANS Picture Naming and DKEFS Verbal Fluency subtests were used to 
assess Language function. For the Picture Naming test, Participants are presented 
with line drawings of 10 objects and asked to name them each, with available 
prompts.  The DKEFS tests also serve as an assessment of executive function.  
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2.7.5. Assessment of Visuo-spatial Function  
The RBANS Figure Copy and Line Orientation subtests were used to assess visuo-
spatial/construction ability.  For the Figure copy subtest, participants are provided 
with a complex drawing, comprising 10 components, presented in black ink on white 
paper, and asked to make a direct copy, with no memorial component involved.  The 
Line Orientation subtest was a 10-item test in which participants were presented with 
a drawing consisting of 13 lines fanning 180 degrees from a central point. 
Underneath this figure, two unlabelled lines were presented. Participants were asked 
to match the lines with the original figure. 
2.7.6. Assessment of Executive Function 
Burgess and Gilbert (2008) advise that the following skills should be assessed as 
part of an assessment executive function; verbal fluency, sequencing, inhibition, 
working memory, and rule deduction. Most tests assess more than one of the above 
elements of executive functioning, and the following tests were chosen accordingly. 
2.7.6.1. The DKEFS Verbal Fluency  
The DKEFS ‘FAS verbal fluency’ subtest includes three separate tests which assess 
the following abilities associated with executive function; Letter Fluency, Category 
Fluency, Switching and Inhibition. These tests are considered sensitive 
measurements of verbal executive function, and place demand upon mental 
flexibility and self-regulation. Optimal performance is dependent upon inhibition of 
inappropriate responses and mental switching between different search strategies 
(Henry et al., 2006). 
In Letter Fluency, participants were told a letter (‘F’, ‘A’, and then ‘S’) and asked to 
say as many words as possible beginning with that letter in 60 seconds. Participant 
were instructed against using proper nouns, nor the same word with different 
endings. In Category Fluency, participants were told a category (‘animals’ and ‘boys’ 
names’) and asked to provide as many exemplars as possible in 60 seconds. In 
Switching, participants were given two categories (‘fruit’ and ‘furniture’) and asked to 
state as many alternating exemplars as possible. Success on these tasks required 
word generation and the ability to follow to specific rules. Each task lasted 60 
seconds.  
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Normative data is provided in the DKEFS test manual, and is based on 1750 
participants aged between 18-89 from United States of America (US). The ethnicity 
of the sample was considered representative of the US population. 
2.7.6.2. The Brixton Spatial Anticipation Test 
The Brixton Spatial Anticipation Test (Burgess & Shallice, 1997) was chosen to 
assess visuo-spatial concept formation/rule deduction. Participants are presented 
with a booklet 56 rectangle cards, each with ten identically spaced circles. The 
participant is required to predict which of the circles will be coloured on the following 
card based on the position of the coloured circle on preceding cards.  
Normative data was obtained on 118 British participants aged between 18-80. 61 
participants were females and 57 males. Race/ethnicity data was not reported. 
2.7.6.3. Trail Making Part A and Part B 
The Trail Making part A and B tests (Reitan & Wolfson, 2001; Reitan, 1955) were 
included to assess visual sequencing and switching skills. In addition to this, Trail 
Making A is also considered a test of information processing speed. For Trail Making 
A, participants are presented with a single A4 sheet containing circled numbers from 
1 to 25 scattered across a page. They are talked through a sample, and then asked 
to connect the circles in numerical order as quickly as possible.  For Trail Making B, 
participants were presented a similar task, but this time the circles containing both 
numbers (1 to 13) and letters (A to L) scattered randomly. The participant must join 
the circles sequentially, alternating between numbers and letters (i.e. 1-A-2-B-3 and 
so forth) as quickly as possible. Normative data for these tests is provided by Davies 
(1968) based on 540 British participants, and is provided in the test manual. 
2.7.7. Assessment of Social Cognition  
The current study chose the adult revised version of the RMET (Baron-Cohen et al., 
2001) and the Social Stories Questionnaire (SSQ; Lawson, Baron-Cohen, & 
Wheelwright, 2004) as two tests of social cognition. In addition to this, the 
Questionnaire of Cognitive and Affective Empathy (QCAE; Reniers et al., 2011) was 
chosen as a self-report measure.  
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Pardini and Nichelli recommend (2009) the use of two different tests of ToM to 
enable a direct comparison within a given population. There are a range of potential 
ToM tests available. However, the current study aimed to address the research 
questions in a manner which would allow the results to be meaningfully compared to 
the results of previous studies exploring social cognition in HAND (Homer et al., 
2013; Ireland, 2011). The limitations and future recommendations identified in said 
research were incorporated into the current methodology: these are addressed 
throughout the method section.  
2.7.7.1. The Reading the Eyes in the Mind Test 
The RMET (Baron-Cohen et al., 2001) is considered a test of emotion recognition 
and emerged from research into social cognition and mentalising ability deficits in 
ASC, a condition characterised by difficulties in social ability and associated with 
impairments in executive functioning skills and ToM: cognitive abilities most 
associated with the pre-frontal cortex.  
Although other tests of emotion recognition are available, for example the  Wechsler 
Advanced Clinical Scale ‘Faces’ test, this test was selected with the intention to 
explore whether the trends reported in previous research would be replicated with a 
different sample. Furthermore, it is a validated for use with a wide range of clinical 
populations and has been reported to be reliable and stable over a 1-year period, in 
a non-clinical sample of adults (Fernández-Abascal, Cabello, Fernández-Berrocal, & 
Baron-Cohen, 2013).  
The RMET is considered to be a visual test (with only a minor element of reading 
required, complimented by a glossary of terms), whereas the SSQ is considered 
largely verbal in its cognitive demand. This difference in the tests is beneficial 
because the substantial reading involved in the SSQ makes it sensitive to language 
bias, whereas the RMET, being mostly a visual-orientated task, is relatively free from 
this concern.  
The development of a valid control condition for the RMET was considered, as 
recommended by Ireland (2011), to explore the potentially influence of language bias 
on test performance. However, the means required to develop such a measure 
proved outside the available resources of the study. An alternative option to 
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developing a control condition was to use instead the child version/original version of 
the RMET (Baron-Cohen, Jolliffe, Mortimore, & Robertson, 1997) which already 
includes a control condition. However, this measure was not appropriate for use with 
an adult population due to its relative simplicity. As such, the present study elected to 
use the revised adult version of the RMET (Baron-Cohen et al., 2001) without a 
control condition, with the view that the tests of speech and language in the wider 
assessment of cognitive would serve as an adequate assessment of the confounding 
effects of language on test performance in the RMET.  
Regarding the administration of the RMET; participants were presented with a black 
and white picture of a face (showing only the eye region) and asked to choose one 
out of a multiple choice of four words which they felt best described the emotional 
state of the person in the picture. Thirty-six items in total, with equal numbers of men 
and women. Each eye image was approximately five by two inches, with two words 
printed above it and two words printed below. Participants were also provided with a 
glossary of terms to check at their leisure, as they were not under timed conditions.  
2.7.7.2. The Social Stories Questionnaire 
The SSQ (Lawson, Baron-Cohen, & Wheelwright, 2004) aims to assess the subjects 
understanding of non-literal cognitive-linguistic social processes required in the 
comprehension of social norms. This test was chosen to explore and build upon 
Ireland’s (2011) findings of impaired performance in HIV-positive adults on the SST ,  
(Happé & Happ, 1994), a test which, although similar in nature, was designed for use 
with children. As a more age-appropriate measure, the SSQ (Lawson, Baron-Cohen, 
& Wheelwright, 2004) was chosen for use in the present study; it contains discreet 
faux pas and was suitable for administering to adult populations. 
The SSQ was originally developed as an adult version of a similar children’s “Faux 
Pax” test (Baron-Cohen, O’Riordan, Stone, Jones, & Plaisted, 1999) and has been 
trialled with adults both with ASC and those considered ‘neuro-typical’ (Lawson, 
Baron-Cohen, & Wheelwright, 2004). As such, this test offered a more subtle 
assessment of subjects’ cognitive social cognition, with a test similar to Ireland 
(2010) but in a manner more appropriate to the target population.  
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Regarding the administration of the SSQ; participants were required to read ten short 
stories which contained within them specific utterances made by one character 
which could upset another in the same story. Each story is divided into three 
sections, with at least four utterances in each section. Prompted by short questions 
at the end of each story, participants were required to identify whether one character 
in the vignette had said something which could be upsetting to another and, if so, 
identify the specific remark which caused offence (from multiple choice options). Ten 
of the sections contained a blatant target utterance, ten contained a subtle target 
utterance and ten contained no target utterance. Participants were scored according 
to the number of targets correctly identified. Each of the ten stories also included a 
control question and only those participants who answered all of these correctly were 
included in the analysis. 
Using the RMET and SSQ together, the assessment benefited from having two tools 
that are described in the literature as assessing different parts of explicit mentalising 
skills; cognitive ToM, and affective ToM. The RMET is considered a test of ‘affective 
ToM’ as it requires the subject to accurately perceive the emotional affect of another; 
this relies on social-perceptual understanding of non-verbal emotional processing. In 
contrast, the SSQ is considered a test of cognitive ToM as it requires the participant 
to understand the cognitive perspective of other people in a social context.  
2.7.7.3. The Questionnaire of Cognitive and Affective Empathy  
The QCAE (Reniers et al., 2011) was chosen as a self-report measure to assess 
empathic experience and behaviour. Furthermore, the inclusion of a self-report 
measure in the present study was done to serve as a point of comparison to the 
performance-based neuropsychological assessment. The selection of three 
contrasting measures is in line with the epistemological position of the study; an 
approach to scientific inquiry which advocates for multiple and varied methods of 
assessment.  
There are a range of available questionnaires which assess social cognition or 
mechanisms within social cognition, including – in no particular order - the Hogan 
Empathy Scale (Hogan, 1969); Interpersonal Reactivity Index (Davis, 1980); 
Empathy Quotient (Baron-Cohen & Wheelwright, 2004); Social functioning scale 
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(Birchwood, Smith, Cochrane, Wetton, & Copestake, 1990); the Socio-Emotional 
Questionnaire (Bramham, Mor, Ho, Bullock, & Polkey, 2009); and, the Empathy 
subscale of the Impulsiveness-Venturesomeness-Empathy Inventory (Eysenck & 
Eysenck, 1978). For the present study, the most recently devised QCAE was 
regarded as the most suitable; its internal items derived from several pre-existing 
measures (including the aforementioned Interpersonal Reactivity Index, Empathy 
Quotient, Hogan Empathy Scale, and Impulsiveness-Venturesomeness-Empathy 
Inventory) and thus benefiting from the strength of these validated questionnaires. 
The QCAE was devised with the view to address the numerous, often conflicting, 
definitions of empathy in the literature, with the aim of drawing these together under 
one working definition of empathy to reflect the multidimensional nature of the 
construct. The measure also delineates cognitive empathy and affective empathy, by 
way of two separable subscales, to reflect the definitional debate regarding whether 
empathy involves recognizing psychological states (i.e., cognitive empathy) or 
experiencing it (i.e., affective empathy). A total of thirty-one items come together to 
provide an overall score that can be separated out into the cognitive empathy 
subscale (QCAE-CES) and the affective empathy subscale (QCAE-AES). Normative 
data is provided by Reniers et al. (2011), based on 925 adults within the United 
Kingdom.  
2.7.8. Assessment of Mood  
The HADS (Zigmond & Snaith, 1983) was chosen as it offered a brief, standardised 
and validated measure with which to assess anxiety and depression. In the 
accompanying literature, the authors state that the measure comprises of two 
separable subscales - anxiety scale and depression scale – which reliably divide into 
four ranges: normal, mild, moderate and severe. For both scales alike, raw scores of 
0 to 7 could be regarded as being in the normal range; scores of between 8 and 10 
acknowledged mild cases; 11–15 moderate cases; and 16 or above, severe cases. 
Furthermore, a score of 11 or higher indicated probable presence ('caseness') of a 
mood disorder and a score of 8 to 10 being just suggestive of the presence of the 
respective milder state (Snaith, 2003).  
The deleterious effects of anxiety and mood on cognitive test performance are well 
documented (Chepenik, Cornew, & Farah, 2007; M. D. Lezak, 2004). As discussed, 
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such difficulties are common alongside HAND and needed to be accounted for 
during the assessment in order for their potential influence on self-reported 
neurocognitive performance as well as performance on neurocognitive tests to be 
taken into consideration.  
2.8. Ethical Issues 
2.8.1. Capacity to Consent 
‘Capacity to consent’ refers to an individual’s ability to make a specific decision for 
themselves: it involves their ability to understand, retain, and weigh up the 
information provided to them, and communicate their decision to others. The Mental 
Capacity Act (2005) states that “…a person lacks capacity in relation to a matter if at 
the material time he is unable to make a decision for himself in relation to the matter 
because of an impairment of, or a disturbance in the functioning of, the mind or 
brain”.   
This study sought to recruit people with some degree of HAND, which, as discussed, 
encompasses a cluster of heterogeneous and fluctuating cognitive impairments. By 
means of numerous cognitive mechanisms, cognitive impairment of this kind can 
directly impair an individual’s ability to provide informed consent, and with this in 
mind, potential participants who were considered to be without capacity to consent 
were not invited to participate. In addition to this, given the fluctuating nature of HIV-
related illnesses and cognitive impairment, it was predicted that participants’ capacity 
to consent might fluctuate throughout the course of their involvement in the study, 
from the point of contact through to their assessment. In light of this, capacity was 
monitored throughout for change by both the researcher and the clinical team. If 
capacity was queried, the researcher sought the guidance of the medical consultant 
and clinical team. It was agreed with the staff teams that anyone deemed as not 
having capacity to consent at any stage throughout the testing process were to be 
withdrawn and any collected data excluded, although this eventuality did not occur 
during the study. 
2.8.2. Informed Consent and Right with Withdraw 
Written consent was obtained from each individual participant prior to testing. A 
Patient Information Sheet (Appendix K) outlined the research aims and procedures; 
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confidentiality; anonymity; the right to withdraw; and provided details the 
researcher’s contact details in case they had any questions post participation. 
Regarding the right to withdraw, participants were informed that they could do so at 
any time with no reason required, and no impact on the care received from the 
service. They were also informed that if they chose to withdraw from the study after 
the data had been anonymised, then the researcher would reserve the right to use 
anonymised data in the current study and further analysis that may be conducted.  
The above information was provided to the participant twice, first verbally by 
telephone and then again at the appointment. This allowed a period of time during 
which to digest and understand the information provided. All participants were 
encouraged to ask questions prior to consenting. If participants agreed to participate, 
they were asked to sign a consent form (Appendix L).  
2.8.3. Confidentiality and Anonymity  
Participant data was handled in line with Trust Confidentiality and participant data 
was anonymised after each assessment was conducted. Participants were assigned 
anonymised identification numbers which were used for all research purposes (e.g., 
record databases and statistical programmes used to analyse the data).  
Participants’ completed test sheets were kept on-site and stored in a locked filing 
cabinets in accordance with the Data Protection Act, 1998. Participants were 
informed about the limits to confidentiality (e.g., in response to a risk to self or 
others) and, that post assessment, the researcher reserved the right to keep the 
anonymised data in order to conduct further analysis (see Appendix K). 
2.8.4. Risk Assessment and Management  
2.8.4.1. Protection of the Participant 
The research design involved no deception. Potential risks to the participant included 
only minor effects such as fatigue and frustration as a result of test performance. All 
possible risks were discussed in the Participant Information Sheet (PIS) to ensure 
full and ethical transparency on behalf of the researcher.  
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To manage these risks, participants were monitored for signs of fatigue and distress, 
and breaks were offered. The researcher agreed in advance with the site teams that 
if participants became distressed during testing, the assessment would be paused, 
rescheduled or terminated.  If anything of significant concern was evident throughout 
the performance (e.g., suicidality or disorientation); the clinical team would have 
been informed immediately.  
At the end of cognitive testing participants were given time to ask questions about 
the administration and discuss their general experience of the assessment. In 
recognition of the numerous potential unknown affects that any assessment may 
have with regards to psychological triggers, particularly in potential vulnerably and 
highly stigmatised clinical population, participants were also provided with 
information signposting them to local community services for continued support in 
the aftermath of the assessment.   
2.8.4.2. Protection of the Researcher 
The researcher was aware of the health and safety policy, fire safety procedures, 
and first aid protocol for each recruitment site. No methodology-specific risks to the 
researcher were identified. However, it was agreed that should any issues arise, the 
researcher would discuss them in supervision with the allocated Director of Studies, 
and if appropriate, with senior clinicians at the recruitment sites. 
2.8.4.3. Protection of the Staff Team 
In both recruitment sites it was agreed that the neuropsychological assessments 
would serve as part of the multidisciplinary service offered by the team. Given that 
neuropsychological test administration and interpretation requires specialist 
knowledge, consideration was given to how the team would manage queries or 
concerns which arose out of the assessment once the research period had finished. 
In Site B, inquiries could be managed by experienced clinical psychologists familiar 
with administering and interpreting neuropsychological tests. However, in Site A, 
where neuropsychological assessments were not part of the service, consideration 
was given to how to protect the staff team from situations such as feeling under-
confident to answer patient questions regarding their neurocognitive assessment. To 
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minimise the risk of this happening, the researcher ensured the neuropsychological 
report included extensive recommendations for rehabilitation and support with 
cognitive functioning, tailored to the participant’s cognitive profile of strengths and 
weaknesses. Participants were also informed about the one-off nature of the 
assessment, and that if they continued to have cognitive concerns then they should 
discuss with their clinician an external referral to the most locally commissioned 
neuropsychology service. 
2.9. Participant Characteristics 
Nineteen participants were recruited, of whom, two opted out before participating 
and one was omitted from analysis due to incompletion of tests in the assessment. 
See Appendix P for full Participant Characteristics information. 
Of the 16 participants included in the analysis, nine were male and seven female. A 
chi-square goodness-of-fit test was conducted to determine whether an equal 
number of participants from each gender were included in the sample (see Table 1). 
The minimum expected frequency was 8. The chi-square test indicated that the two 
gender categories were equally represented (x2 (1) = .250, p = .804).  
The participant characteristics data was examined to explore whether the distribution 
of variables met the assumptions for non-parametric examination (Field, 2013). Age, 
summative education, CD4 count and HADS-anxiety raw scores were normally 
distributed (Skewness <1, Kurtosis <3, and Shapiro Wilk Significance > .05). In terms 
of measures of variability, all had large standard deviations.  The mean age was 43.9 
years old (range: 24 to 69); representing a working age adult sample. Nine 
participants were born in the UK (5 white British, 4 black British), all of whom had 
English as their first language. For the remaining seven, their countries of origin 
included Uganda, Burundi, Spain, Portugal, Singapore, and Somalia.  
Premorbid ability was assessed using WTAR, total years of education, and highest 
preserved score. The mean summative education was 12.8 years (range of 6 to 19 
years). All participants were able to speak and read English fluently. The mean 
WTAR Scaled Score was very slightly lower than the population mean, with a large 
standard deviation indicating a wide range in scores. This suggests that this 
sample’s WTAR average score may not be representative of population mean.  
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All participants had a diagnosis of HIV with subjective cognitive complaints. With 
regards to physical co-morbidity; two participants had received treatment for 
Kaposi’s sarcoma; one participant had Hepatitis C; and, one participant had 
undergone a Hysterectomy. Psychological co-morbidity was assessed using the 
HADS (Zigmond & Snaith, 1983); the mean raw score on the anxiety scale was 8.75; 
the mean raw score on the depression subscale was 7.25. The test’s authors 
recommended that, for the anxiety and depression scales alike, raw scores of 
between 8 and 10 identify mild cases, 11–15 moderate cases, and 16 or above, 
severe cases. Thus the sample demonstrated mild elevated levels of anxiety 
compared to the typical population; a profile consistent with the literature (Rabkin, 
2008; Shacham, Morgan, Önen, Taniguchi, & Overton, 2012) 
Participants most recent CD4 count, viral load and diagnosis date were also noted 
for profiling purposes only. However, as diagnosis date did not represent the length 
of HIV illness, but contact with tertiary services, it was not included in the analysis. 
This cohort were a working age adult sample, equally matched for gender, reporting 
with mild levels of anxiety. Ethically and culturally diverse, they all spoke fluent 
English, and were mostly virologically controlled and cART-adherent; and, 
accordingly, this is the population for which the consequent results will m 
 
Table 1: Descriptive Statistics for Participant Characteristics 
 Mean SD Min Max Skewness Kurtosis Shapiro-
Wilk 
(sig.) 
Age  43.9 10.5 24 69  .487   1.336 .674 
Education 12.81 3.22 6 19 -.242   .442 .553 
WTAR 9 4.24 13   1 -1.08  -.120 .005 
HADS – 
Anxiety  
8.75 4.69 2 17 .352 -.894 .489 
HADS – 
Depression 
7.25 4.49 2 18 1.283 1.104 .018 
CD4 583.38 218.570 1 954 -.549   0.848 .846 
VL 49758.25 159780.82 1 642167 3.856 15.130 .000 
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3. RESULTS 
Information converting scaled scores into subjective labels is located in Appendix N. 
3.1. Initial Exploration and Initial Analysis of Cognitive Tests 
The sample’s neurocognitive test data (scaled scores) were analysed first with a 
view to examine the general cognitive profile of the group before considering more 
specific deficits. The data was not normally distributed since many of the values 
were skewed and kurtosed (Skewness >1 and Kurtosis < 3); therefore, further 
analysis proceeded with non-parametric approaches (see Table 2). 
A comparison of the subtest mean scores showed that performance on all of the 
neurocognitive tests fell within the ‘average’ range. Of these, there were six tests for 
which group performance fell lowest, including; Digit Forward, Fluency (Category), 
List Total, List Delay, Story Immediate, Story Delay. Standard Deviations were for all 
of these tests - except for Story Immediate and Story Delay - were large, indicating 
wide variability within subtest scores. Overall, these scores show that, at a group-
level of analysis, this cohort demonstrated no impairment in any particular domain, 
suggesting that any forthcoming difficultly observed on social cognition tests will not 
be attributable to a core deficit.  
As shown in Table 3, non-parametric Kolmogorov-Smirnov one-sample tests were 
used to compare sample means to hypothesised distribution (Mean: 10, SD: 3). 
Tests indicate that the mean scaled scores for Figure Copy, Line Orientation,  
Fluency (Letter) and Trails B in this sample were significantly different to the 
performance of the typical population.  
3.2. Initial Exploration and Initial Analysis of Social Cognition Tests 
A comparison of the social cognition test means (see Table 4) showed that 
performance on the RMET and SSQ fell in the ‘low-average’ range. Again, the 
standard deviations for these tests were large, indicating wide variability between 
individual subtests scores. Overall, these results demonstrate that performance 
scores on the RMET and SSQ were the most diminished in this cohort, out of all 
administered tests in the current study.  
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Non-parametric Kolmogorov-Smirnov one-sample test was used to compare sample 
means to hypothesised distribution (Table 5). Results indicate that the mean scaled 
scores for the RMET and SSQ in this sample were significantly different to the 
performance of the non HIV-positive population.  
3.3. Associations between Variables 
Spearman’s Rho analyses were conducted to explore the relationships between 
demographic variables (age, education, reading ability, total HAD raw score) and 
neurocognitive test raw scores (social cognitive tests, List Total, Story Immediate, 
Category Fluency) based on areas of declined performance as identified in prior 
analysis of subtest means. Although no weaknesses in visuo-spatial function were 
observed, Figure Copy was also included in the analysis to explore an association 
with the RMET due to the substantial visual component in the cognitive burden of the 
RMET. Key associations and medium to large effect sizes are reported below (i.e. > 
0.333). The full correlation matrix is given in Appendix O. 
3.3.1. Age  
Age did not correlate with either social cognition test, but had a moderate negative 
association with List Total (r = -.448) 
3.3.2. Education  
As would be expected, total years of education correlated with reading ability 
(WTAR; r = .741); List Total (r = .403); Story Immediate (.618); and Verbal Fluency 
Categories (r = .476). Of note, education also had a mild-moderate correlation with 
SSQ (r = .444) and QCAE-CES (.401).  
3.3.3. Affect 
The total HAD score has a weak correlation with the RMET (r =.383), and a 
moderate negative correlation with and SSQ (r = -.482), and QCAE-CES (r = -.462).  
3.3.4. Verbal Function 
The WTAR (i.e., ‘reading ability’ and ‘language facility’) had a strong correlation with 
education (r = .741); a moderate correlation with Story Immediate (r = .598) and 
Category Fluency (r = .527); and, a weak correlation with List Total (r -.331).  Of 
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note, the WTAR also had a moderate correlation with the QCAE-CES (r = .525), and 
a weak correlation with the SSQ (r = .387).  
The List Total subtest had a strong correlation with the Story Immediate subtest (r = 
.652), and a moderate correlation with the SSQ (r = .541) and QCAE-CES (r = .522). 
The Story Immediate subtest had a weak correlation with the QCAE-CES (r =.378).  
3.3.5. Verbal Executive Function  
The Verbal Fluency Category Test had a strong correlation with the List Total subtest 
(r = .730) and the Story Immediate subtest (r = .725).  
The Verbal Fluency Category Test also had a weak correlation with the SSQ (r = 
.381) and QCAE-CE (r = .393). 
3.3.6. Visual Function 
The Figure Copy subtest had a weak correlation with the WTAR (r = .371) and the 
List Total (r = .390); and a moderate correlation with the Story Immediate (r = .585). 
No correlation was found with the RMET or any of the other social cognition group 
scores.  
3.3.7. Associations between Social Cognition Tests  
The SSQ and the RMET did not correlate with one another (r = .013). Similarly, the 
two QCAE subscales did not demonstrate a remarkable correlation with one another 
(r = .259). 
The only notable correlation between the social cognition tests was found between 
the SSQ and QCAE-CES (r = .684). This association was not also reflected between 
the SSQ and the QCAE-AES (r = .098). 
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Table 2: Descriptive Statistics and Distribution Analysis for Neurocognitive 
Test Means (Scaled Scores) 
 
 
 
 
 Mean SD Min Max Skewness Kurtosis Shapiro-Wilk 
(sig.) 
WTAR  9 4.24 1 13 -1.08 - 0.120 .005 
Digit Forward 8.13 3.737 2 14 - 0.330 - 0.870 .430 
Coding 10.06 3.356 4 17   0.567   0.287 .364 
Trails A 9.38 3.403 1 13 - 1.678   2.439 .001 
Picture 
Naming 
9.88 3.117 1 12 - 0.860   3.487 .000 
Figure Copy 11.00 2.394 5 13 - 1.665   2.371 .001 
Line 
Orientation 
11.94 3.130 7 15 - 0.799 - 1.176 .002 
Fluency  
(Letter) 
9.25 5.580 3 18   0.382 - 1.628 .021 
Fluency (Cat) 8.56 4.066 1 17   0.172   0.121 .977 
Fluency 
(Output) 
10.38 4.209 1 16 - 0.784 - 0.065 .269 
Fluency 
(Switch) 
10.06 3.941 3 16 - 0.262 - 1.015 .600 
Brixton 10.25 3.454 2 14 - 1.195   1.054 .034 
Trails B 10.81 3.449 1 14 - 1.903   3.851 .001 
Trails Ratio 11.94 1.843 9 16   0.469   0.019 .671 
List Total  8.31 3.301 3 15   0.320 - 0.547 .553 
List Delay 8.94 3.924 1 16 - 0.249 - 0.043 .927 
List 
Recognition 
9.81 3.391 1 12 - 1.845   2.637 .000 
Story 
Immediate 
8.06 2.863 4 12 - 0.247 - 1.491 .063 
Story Delay 8.81 2.482 4 13 - 0.293 - 0.295 .677 
Figure Delay  9.69 3.945 4 16   0.177 - 1.344 .253 
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Table 3: Kolmogorov-Smirnov Test for Neurocognitive Tests Means (Scaled 
Scores) 
Neurocognitive Test. N Test 
statistic 
 sig. 
WTAR  16 .772 .590 
Digit Forward 16 1.022 .247 
Coding 16 .750 .627 
Trails A 16 .978 .295 
Picture Naming 16 1.010 .259 
Figure Copy 16 1.522 .019* 
Line Orientation 16 2.115 .000* 
Fluency – Letter 16 1.635 .010* 
Fluency – Category 16 1.240 .092 
Fluency – Output 16 1.240 .092 
Fluency – Switches 16 .772 .590 
Brixton 16 .990 .281 
Trails B 16 1.500 .020 
List Total  16 1.385 .043 
List Delay 16 .990 .281 
List Recognition 16 1.272 .079 
Story Immediate 16 1.228 .098 
Story Delay 16 1.272 .079 
Figure Delay  16 .990 .281 
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Table 4: Descriptive Statistics and Distribution Analysis Social Cognition Test 
Means (Scaled Scores) 
 
Table 5: Kolmogorov-Smirnov Test for Social Cognition Test Means (Scaled 
Scores) 
 
Table 6: Non-Parametric Bivariate Correlation Analysis with Social Cognition 
Tests (Raw Scores) 
Social Cognition Test. RMET SSQ QCAE-CES QCAE-AES 
RMET 1.000 .013 -.304 -.042 
SSQ .013 1.000 .684 .098 
QCAE-CES -.304 .684 1.000 .259 
QCAE-AES .167 .098 .259 1.000 
 
Table 7: Multiple Linear Regression to Explore Contribution to QCAE-CES 
score (Raw Scores) 
Neurocognitive test. Beta. t. Sig. 
WTAR  .390 1.377 .151 
Education (total years) -.050 -.174 .865 
List Total  .180 .733 .479 
SSQ  .386 1.576 .143 
 
 
 
Social 
Cognition 
Test. 
Mean SD Min Max Skewness Kurtosis Shapiro-Wilk (sig.) 
RMET 7.63 3.442 2 13 -.140 -.881 .578 
SSQ 7.69 4.078 3 16 .885 .441 .035 
QCAE-CES 8 4.367 1 14 -.653 -.904 .024 
QCAE-AES 9 4.195 1 14 -.718 -.150 .089 
Social Cognition Test. Df. Test statistic sig. 
RMET 16 1.522 .019* 
SSQ 16 1.990 .001* 
QCAE-CES 16 1.059 .212 
QCAE-AES 16 0.750 .627 
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3.4. Individual Profile Analysis 
Each participant’s cognitive profile was examined in the context of their relevant 
background information obtained from their clinical interview and medical files.  
For each participant, a graph displays their distribution of converted scaled scores 
for performance on the HAD scales, social cognition tests, QCAE subscales, and 
neurocognitive battery.  
For each participant, pre-morbid ability was estimated using reading ability as an 
overlearned ability (as measured using the WTAR), educational attainment (as 
measured by total years of education) and highest score among tests as an 
indication of level of ability. In this manner, pre-morbid ability was assessed by 
comparing participants to both the normative population (WTAR) as well as 
comparing them to themselves (highest score) and educational achievements. 
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Participant 1  
Participant 1 was a fifty-seven year old white British male, born and educated in the 
UK.  With English as his first language, he attended school from five to twenty-one, 
obtaining an undergraduate university degree. Occupation; employed full-time in 
professional management.  
cART adherent, he was on his second cART regime since diagnosis (CD4 count = 
575, = VL = 1, diagnosed = 2012). He had a history of depression and anxiety but 
was currently below-caseness on the HAD. His father had been diagnosed with 
Dementia of the Alzheimer’s type in later life.  
 
Figure 1: Scaled Scores for Participant 1 
Figure 1 shows an intact unimpaired cognitive profile, with minor weaknesses in digit 
forward performance, in keeping with normal variation.  Furthermore, the SSQ and 
QCAE subscale scores fall in the ‘very superior’, ‘average’ and ‘high average’ 
ranges, respectively.  
In contrast, the RMET score falls in the ‘average’ range, suggesting impaired 
emotion recognition abilities. 
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Participant 2  
Participant 2 was a forty-one year old black British male. Born and educated in the 
UK, he attended school from five to twenty-one years of age; obtaining 
undergraduate university degree. Occupation; full-time senior accountant. No current 
or historic cART use (CD4 count = 512, VL = 22174, diagnosed = 2014).  HAD 
scores; below-caseness.  
 
Figure 2: Scaled Scores for Participant 2 
Figure 2 shows a cognitive profile with relative weaknesses in verbal fluency and 
verbal recall. This may reflect normal variation, or emerging difficulties with 
concentration and attention consistent with ANI.  
All four social cognition scores are within the ‘average’ range for the normal 
population but towards the lower end of overall ability the context of the participants 
own specific cognitive profile.  
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Participant 3  
Participant 3 was a thirty-three year old black British male. Born and educated in the 
UK: he attended school from five to twenty-one, obtaining an undergraduate 
university degree. With English as his first language, he also spoke two other 
languages fluently. Occupation: full time administrative work, and a civil rights 
advocate. He did not currently or historically take any cART (CD4 count = 587, VL = 
42909, diagnosed = 2009). HAD scores: below-caseness. 
 
Figure 3: Scaled Scores for Participant 3 
Figure 3 shows a cognitive profile with relative weaknesses on following subtests: 
Coding, Figure Copy, List and Story Immediate Recall. This may represent an 
emerging decline in attention and memory, consistent with ANI. 
RMET, QCAE-CES and SSQ scores all fell in the ‘average’ range. In contrast, the 
QCAE-AES score fell in the ‘low-average’ range; with any impairment unlikely to be 
influenced by core deficits given comparative scores. 
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Participant 4  
Participant 4 was a forty year old black Ugandan female. Born and educated in 
Uganda: she attended school from five to sixteen, including a short time at boarding 
school. A primary speaker of Luganda, she also spoke fluent English. Occupation; 
unemployed. She has a complex history of adverse and traumatic life experiences, 
and in 2013 she met with a Psychologist for support with severe anxiety, depression, 
and trauma. At the time of testing, she did not have symptoms associated with ‘Post-
Traumatic Stress Disorder’, anxiety or depression: HAD scores: below-caseness.  
(CD4 count = 529, VL = 1, diagnosed = 2011).  
 
Figure 4: Scaled Scores for Participant 4 
Figure 4 shows a cognitive profile with relative weaknesses in verbal attention, 
semantic verbal memory, and verbal executive function tests. ‘Average’ performance 
on the list-based learning and memory tests support the likelihood of an intact ability 
to encode and store information. Although these impairments may be overestimated 
due to second-language status, they are nonetheless consistent with the 
participant’s subjective cognitive complaints and therefore might represent an 
emerging attentional or executive function weakness, consistent with MND. The SSQ 
score fell in the ‘high-average’ range and the QCAE-CES score fell in the ‘average’ 
range. In contrast, the RMET and QCAE-AES scores fell in the ‘impaired’ range and 
below.  
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Participant 5  
Participant 5 was a forty-eight year old black Somali woman. Born and educated in 
Somalia with her 12 siblings, she attended school between the seven and fourteen 
years of age. She spoke Swahili and Somali as first languages, and also spoke 
fluent English.  Occupation: unemployed. cART regimen changed seven times since 
2003 due to side-effects and viral resistance, and twice admitted to HIV inpatient 
ward (CD4 count = 76, VL = 642167, diagnosed = 2003). Prescribed Mirtazapine for 
depression; she subjectively reported mild low mood, but reported severe depression 
on the HADS.  
 
Figure 5: Scaled Scores for Participant 5 
Figure 5 shows substantial impairment in processing speed, verbal and visual 
immediate memory, attention (e.g., encoding of to-be-learned material) and 
executive functions. The SSQ and QCAE-CES scores fell in the ‘impaired’ and ‘very-
impaired’ ranges, respectively: suggesting a weakness in these areas separate to 
both the other two measures of social cognition. In the clinical interview, participant 5 
self-reported marked functional decline in activities of daily living (ADLS) that were 
not attributable to co-morbidities or delirium. She demonstrated functional 
impairment in her unemployment due to cognitive impairment and self-report of 
dependence. Alongside the apparent moderate to severe cognitive impairment 
shown above, this profile is consistent with HAD although attribution of impairment to 
HAND is confounded by severe depression scores. 
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Participant 6 
Participant 6 was a thirty-six years old white Spanish woman. Born and educated in 
Spain, she attended school from five to eighteen years of age, after which she 
moved to the UK where she obtained an undergraduate university degree in English 
Literature at the age of twenty-three. With Spanish as her first language, she was 
also fluent in English. Occupation: full time Research Nurse. cART commenced 4 
weeks prior to testing (CD4 count = 441, VL = 88608, diagnosed = 2001). History of 
‘Post-natal Depression’ and mild crone’s disease, with no present symptoms of 
either. HAD scores; mild depression. 
 
 
Figure 6: Scaled Scores for Participant 6 
Figure 6 shows a strong cognitive profile consistent with estimated pre-morbid ability 
and normal variance, showing no evidence of impairments characteristic of HAND.  
Scores on the QCAE subscales are slightly lower than others in the profile, however, 
any real-world difficulties here may be compensated for by the relative strengths in 
areas of executive function, particularly on tasks which required mental flexibility and 
multiple demands.  
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Participant 7  
Participant 7 was a sixty-seven year old white British man. Born and educated in the 
UK, he attended Private School from five to eighteen years of age. Occupation; 
Horse-trainer, now retired. cART adherent; he described some tiredness and 
‘slowing-down’ which he attributed to side effects (CD4 = 418, VL = Und, diagnosed 
= 1993). Currently treated for Shingles in left eye which caused some blurred vision. 
History of anxiety and depression though not currently: HAD scores; below-
caseness. 
 
Figure 7: Scaled Scores for Participant 7 
Figure 7 shows a cognitive profile with impaired performance on verbal executive 
function and some tests of learning and memory (List Total, List Delay, Figure 
Delay). That said, performance on Story Immediate, Story Delay and List 
Recognition subtests fall in the ‘average’ range, implying either normal variation or 
an emerging difficulty with episodic memory function and/or attention. This profile is 
consistent with ANI. 
Both QCAE subscale scores fell in the ‘average’ range or above. In contrast, the 
RMET and SSQ scores fell in the ‘low-average’ and ‘below- normal’ range, 
respectively; suggesting an impairment in mentalising ability not secondary to core 
deficits or mood. 
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Participant 8  
Participant 8 was a forty-nine year old black British woman. Born in the UK, she 
moved to Jamaica when five years old where she attended school from five to 
seventeen. Occupation; full time cleaner and an active member of her church 
community. cART adherent (CD4 count = 954, VL = Und, diagnosed = 2005). HAD: 
mild depression.  
 
Figure 8: Scaled Scores for Participant 8 
Figure 8 shows relative weaknesses in verbal and visual memory and executive 
function abilities; representing an emerging memory or executive function cognitive 
difficulty, consistent with HAND. In the clinical interview, participant 8 self-reported 
mild decline in everyday functioning including significant reduction in occupational 
responsibilities secondary to reduced cognitive abilities and decline in vocational 
functioning. This profile, alongside information collected in the clinical interview 
identified it as being consistent with emerging MND. 
The SSQ score fell in the ‘low average’ range. In contrast, the RMET and both 
QCAE subscale scores fell in the ‘impaired’ range; suggesting greater impairment in 
emotion recognition and empathy.  
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Participant 9  
Participant 9 was a forty-one year old black Ugandan woman. Born in Uganda, she 
was educated in Kenya from five to thirteen years of age, which she enjoyed but 
stopped attending due to the school’s corporal punishment. In the UK, she attended 
and passed a college ESOL course in English language skills and is fluent in 
English. Occupation: full time shop assistant and single mother of two. cART 
adherent (CD4 count 594, VL = Und, diagnosed 2005). Medical history including 
Hypercholesterolaemia; Hypertension; Endometriosis; and a sub-total hysterectomy 
in 2014. HAD: severe anxiety. 
 
Figure 9: Scaled Scores for Participant 9 
Figure 9 shows relative weaknesses in verbal attention, verbal memory, and verbal 
executive function tests as well as severe anxiety.  
RMET scores and QCAE-AES scores fell in the ‘high-average’ and ‘average’ range, 
respectively. In contrast, SSQ and QCAE-CES scores fell in the ‘impaired’ range. 
Although second-language status and presence of severe anxiety restrict 
interpretation, these impairments are consistent with the participant’s subjective 
cognitive complaints and therefore might represent emerging attentional, memory or 
executive function weakness, consistent with MND.  
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Participant 10  
Participant 10 was a forty-two years old white Portuguese woman. Born and 
educated in Portugal, she attended school from five to seventeen years of age. With 
Portuguese as her first language, she also speaks fluent English. Occupation; 
mother of three, part-time administrator, and an active member of a PTA group. 
cART adherent (CD4 count = 687, VL = Und, diagnosis = 2000); she also has a 
diagnosis of Hepatitis C, and was previously treated for mouth cancer. HAD scores; 
moderate anxiety and depression. 
 
 
Figure 10: Scaled Scores for Participant 10 
Figure 10 shows relative weaknesses in tests of attention (Letter Fluency, Digit Span 
Forwards and Backwards). These are consistent with subjective complaints of poor 
memory, verbal repetition and ‘zoning out’ during familiar tasks and may reflect an 
emerging attentional deficit, consistent with ANI. 
The RMET, QCAE-AES and SSQ scores all fell in the ‘average’ range, whereas the 
QCAE-CES scores fell in the ‘below-normal’ range.   
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Participant 11 
Participant 11 was a forty-nine year old black British man. Born in Ghana and 
educated in the UK from five to twenty-three years of age, obtaining a post-graduate 
qualification. Occupation; senior professional role. He was cART adherent (CD4 
count = 869, VL= Und, diagnosis = 2002) and had a history of recurrent depressive 
episodes, but was not at the time of testing. HAD scores; mild depression.  
 
Figure 11: Scaled Scores for Participant 11 
Figure 11 shows a cognitive profile mostly in keeping with the estimated high 
average pre-morbid ability. However, subjective complaints concerned reduced 
processing speed and attention over last 18 months, and the cognitive profile may be 
suggestive of early emerging difficulties with processing speed and attention, in 
keeping with emerging ANI. 
RMET and QCAE-AES scores both fell in the ‘below-normal’ range, whereas SSQ 
and QCAE-CES fell in the ‘low average’ and ‘average’ range, respectively.  
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Participant 12 
Participant 12 was a forty-three year old black British woman. Born and educated 
Burundi, she attended school from five to sixteen and, in the UK, later completed 
GCSEs in Maths, English and ICT, and started HND qualifications in English and 
Maths. She found latter studies difficult to engage with due to cognitive complaints. 
She came to the UK after first seeking asylum in Kenya due to the Burundi civil war. 
Her first languages are French and Swahili, and she also spoke fluent English. 
Occupation; unemployed, previously a supermarket cashier. She was cART 
adherent (CD4 count = 580; VL = Und; diagnosed = 2006) and reported current low 
mood and interpersonal difficulties. HAD scores; moderate mixed anxiety and 
depression.  
 
Figure 12: Scaled Scores for Participant 12 
Figure 12 shows that performance on Trails A, Picture Naming, Fluency (Category 
and Switching) and Trails-B subtests all fell in the ‘profoundly’ impaired range; a 
pattern of impairment consistent with MND. Areas of impairment may be 
overestimated due to secondary language status and the confounding impact of co-
morbid severe depression.  
RMET and QCAE-AES scores fell in the ‘low average’ and ‘average’ range, 
respectively. In contrast, the SSQ and QCAE-CES scores fell in the ‘impaired’ and 
‘very-impaired’ range, respectively.  
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Participant 13 
Participant 13 was a forty-eight year old white British male. Born and educated in 
England, he completed a combination of private and state education between five to 
twenty-one years of age, obtaining a BTech Diploma. Occupation; unemployed and 
receiving ESA; previously employed in the Bar and Restaurant Industry. He is cART 
adherent (CD4 count = 704, VL = Und; diagnosis = 1997). Treated for Kaposi's 
sarcoma last year, currently experiencing poor sleep and fatigue. HAD scores; 
severe anxiety.  
 
Figure 13: Scaled Scores for Participant 13 
Figure 13 shows a mostly strong cognitive profile, but with ‘low average’ 
performance on the Digit Forward and List Learning subtest. However, there was 
strong performance on Story Learning, another test of immediate memory, signifying 
intact encoding and retrieval. Profile consistent with ANI, although impairments may 
be interrelated with severe anxiety score.  
Social cognition test scores were amongst the weakest in the profile. Although 
RMET and QCAE-CES scores fell in the ‘average’ range; the QCAE-AES score fell 
in the ‘low average’ range, and SSQ in the ‘below-normal’ range.  
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Participant 14  
Participant 14 was a twenty-three year old Malaysian male. Born and educated in 
Singapore, he attended school from four to eighteen, before completing two years of 
mandatory Army conscription in Singapore and moving to the UK to attend 
university. cART adherent, reported no side-effects and good current and historical 
health. (CD4 count =282, VL = 263, diagnosed = 2015). He reported experiencing 
cognitive changes after HIV infection, and again when starting the antiretroviral 
treatment, including a decline in processing speed and attention span. However, he 
feels like these difficulties have abated since. HAD scores; mild anxiety. 
 
Figure 14: Scaled Scores for Participant 14 
Figure 14 shows a well persevered cognitive profile. Slight weakness on List and 
Story Learning performance can be accounted for by performance anxiety 
experienced at time of testing.  
The SSQ and QCAE subscale scores fell within the ‘high average’ range. In contrast, 
RMET was in the ‘below-normal’ range suggesting impaired emotional recognition 
abilities, not attributable to visual and language deficits. 
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Participant 15 
Participant 15 was a thirty-three year old white British man. Born and educated in the 
UK, he attended school between five to sixteen years of age and remembers 
receiving additional learning support in secondary school. Occupation; full-time chef. 
He was cART adherent, on his second cART regime after experiencing adverse side 
effects from the first, including nightmares, nausea and dizziness (CD4 count = 720, 
VL= Und, diagnosed = 2012). He described a period of depression following his 
diagnosis, but no symptoms at the time of testing. HAD scores; moderate anxiety. 
 
Figure 15: Scaled Scores for Participant 15 
Figure 15 shows significant weaknesses on a test of Letter Fluency and List Delay 
(but average performance on Story Delay); suggesting a possible impairment in 
episodic learning or verbal function. This is consistent with subjective complaints of 
impaired short-term memory and is in keeping with emerging ANI.  
Substantial impairment on the RMET and milder impairment on the SSQ are also 
observed, suggesting a disadvantage in emotional recognition and cognitive-
linguistic skills not attributable to other core deficits. 
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Participant 16 
Participant 16 was a fifty year old white British man. Born and educated in England, 
he attended school from five to eighteen years of age. He spent the first two years of 
his life in state provided child-care, after which he was moved to live with his mother. 
He described a difficult home-life growing up, which impacted his educational 
attainment. He was rarely absent from school, but struggled with Maths and English. 
Occupation; self-employed carpenter and set up his own business. He is cART 
adherent (CD4 count = 806, VL = Und, diagnosed = 1996). He partook in the 
SMART Research Trial, where he discontinued his cART for a controlled period of 
time in order to investigate his immune response: during this time he developed 
shingles and some minor infections before re-starting cART. HAD scores; mild 
anxiety.  
 
Figure 16: Scaled Scores for Participant 16 
Figure 16 shows a profile of scores which fall in ‘average’ range and above on most 
tests; likely revealing an intact cognitive profile. Profound weakness on two tests of 
delayed memory (List and Story Recall) may be associated with performance anxiety 
at the time or testing, as corroborated by patient subjective feedback. Alternatively, 
these weaknesses may also be consistent with an emerging attentional deficit, in 
keeping with the patient’s subjective cognitive complaints. As such, this profile is 
consistent with HAND of the ANI nature.  
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4. DISCUSSION  
This study aimed to explore the cognitive profile of social cognition in HAND. The 
research questions specially sought to address whether HAND differentially affected, 
cognitive-linguistic function (e.g., comprehension of non-literal language), emotion 
recognition (e.g., of facial expression), or empathy (e.g., capacity to emotionally 
engage with other persons).  
4.1. Summary of Results 
This study revealed that a cohort of 16 adults with HIV-1 infection demonstrated 
weaker performance on two measures of social cognition (i.e., RMET and SSQ) than 
people without HIV (i.e., test norms). Group-level analysis showed that these trends 
occurred in the context of a cohort with relatively well preserved level of cognitive 
functioning, with only mild weaknesses in attention, verbal learning and semantic 
verbal executive function. Individual-level analysis revealed that the social cognition 
impairments typically occurred alongside other areas of decline and not before, and 
were not related to stage of HIV infection. These findings support the previous 
research into the profile of social cognition impairments in HAND (Homer et al., 
2013; Ireland, 2011). Taken together, these results indicate that impairments in the 
cognitive processes required for some aspects of social cognition (e.g., non-literal 
cognitive-linguistic processing and emotion recognition) may be characteristic of the 
neurocognitive profile of HAND, even in relatively mild stages of cognitive 
impairment.  
The sections below offer a thorough breakdown of the above findings, including an 
analysis of the pertinent and confounding variables. An itemisation of the group-level 
analyses are offered first, and then considered within the context of the trends 
revealed by the Individual Profile Analyses.  
4.2. Discussion of Group-Level Analysis  
The findings from the subtest means and correlational analyses are discussed 
below. Whilst correlations do not demonstrate causality, they are useful at 
suggesting relationships between variables and identifying areas for further 
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exploration. However, the following results should be taken as representing trends in 
the data only. 
4.2.1. General Cognitive Function 
As an initial overview of the sample’s general cognitive functioning prior to more in-
depth interpretation; only mild weaknesses were apparent on Digit Forward (mean 
8.13); Category Fluency (mean 8.56); List Total (mean 8.31) and Story Immediate 
(mean 8.06); suggesting minimal decline in areas of attention, verbal learning and 
executive function. Intact domains included; information processing (Coding and 
Trails A), visuo-spatial function (Line Orientation and Picture Copy) and visual 
executive function (Brixton Test and Trail Making B). However, as noted, all of these 
subtest means had large standard deviations. These trends appeared consistent 
with the literature regarding the characteristics of emerging HAND in the post-cART 
era  (Iudicello, Woods, et al., 2012; Iudicello et al., 2008; Woods et al., 2009). 
The specific areas of cognitive decline and interpretations of these finding are 
provided further below.  
4.2.1.1. Attention and Information Processing 
As stated, the group demonstrated performance in the low-average range on the 
Digit Span task, which serves as an assessment of verbal short-term memory stores 
and attention. Although previously thought to be a faculty relatively spared until later 
stage of disease progression, more recent literature purports that attentional deficits 
may be among the earliest to develop in HAND (Butters et al., 1990; Heaton et al., 
1995; Levine et al., 2008). It is possible that this area of weakness also contributed 
to the lower group mean on the List Total task (see below). 
4.2.1.2. Learning and Memory 
Mild decline was observed on both the List Total and Story Immediate; tests of 
verbal learning and memory, whereas performance on the List Recognition task was 
within the average range. These results are in keeping with current research, on two 
counts; that which identifies that both tests are sensitive to HAND (Igor Grant et al., 
2008; Woods et al., 2009), and that HAND typically sees impairment in learning new 
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information, whilst recognition and cued memory remain unaffected until the later 
stages of infection (Heaton et al., 1995; Iudicello, Kellogg, et al., 2012).  
4.2.1.3. Executive Function  
Performance on all tests of executive function fell in the ‘average’ range, with the 
exception of Category Fluency, on which the group demonstrated ‘low-average’ 
performance. This latter result is consistent with the literature which reports that  
verbal fluency impairment is the most frequently identified language deficit in HIV 
and is estimated to occur in approximately 40% of the population (Rippeth et al., 
2004). 
Additional impairments in executive function are reported as prevalent in post-cART 
HAND presentations (Gates & Cysique, 2016; Heaton et al., 2015; Woods et al., 
2009) and the absence of such impairments in the current cohort may reflect the 
wide variability in the test scores obscuring impairments at a group-level. This theory 
is explored further in the coming Individual Profile Analysis. 
Accordingly, therefore, impaired performance on the social cognition tests could not 
be explained by executive dysfunction. This provides support for the ‘domain 
specific’ notion, discussed in the introduction; that, rather than being solely reliant on 
executive function mechanisms, there is instead some degree of specificity to social 
cognition (Kipps & Hodges, 2006; Stone & Gerrans, 2006). These results draw 
similarly upon Frith and Frith’s (2012) model of social cognition, supporting the view 
that the processes which make up social cognition – despite drawing largely on 
general cognitive mechanisms – may also require specialist processes which are yet 
to be fully understood. 
4.2.2. Social Cognition 
As an initial overview of the cohort’s social cognition functioning prior to more in-
depth interpretation; this cohort performed in the ‘low-average’ on both 
neurocognitive tests of social cognition; RMET (mean 7.63) and SSQ (mean 7.69). 
These were the largest disadvantages demonstrated on all the tests administered in 
the current study. QCAE scores for each subscale fell in the ‘average’ range.  
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4.2.2.1. RMET 
The cohort demonstrated impaired performance on the RMET (equal to one 
standard deviation below the norm) suggesting disadvantaged emotion recognition 
skills. In addition to emotional recognition, successful performance on this task also 
required intact visual function and reading ability in order to visually scan the eye 
region of the image, and read the complex emotion-based lexicon. A review of the 
subtest means revealed that no equivalent group-level impairments were apparent in 
visuo-spatial function: a finding in keeping with the wider literature which reports that 
visual function remains intact until later stages of HIV infection (Heaton et al., 1995). 
With regards to reading ability, the cohort demonstrated slightly poorer performance 
on the WTAR than the population norm. Although this score was still within the 
‘normal’ range, it might indicate a very mild weakness in this area which may have 
contributed to their performance on the RMET. However, this association was not 
reflected in the results of the correlational analyses (see Appendix O). As such, 
these findings suggest that the declined performance on the RMET was separate to 
both reading ability and visuo-spatial function, in this cohort.  
4.2.2.2. The SSQ 
The sample also demonstrated impaired performance on the SSQ. This test relies on 
several complex cognitive demands, including; a memorial component; several 
verbal and linguistic demands; the ability to identify violations in social norms; and, 
explicit mentalising skills. Therefore, success on this test requires the operation of 
several cognitive processes, and impaired performance can be secondary to various 
areas of weakness. To consider the role of verbal function here, relevant subtest 
means were compared. The SSQ requires intact reading skills, and, as discussed, 
the group performance on the WTAR was slightly lower than the population norm. 
Furthermore, Picture Naming, List Total, Story Immediate and Category Fluency all 
have primary linguistic and verbal components. Although performance on the former 
of these subtests appeared intact, there were mild weaknesses apparent on the 
latter three. Further correlational analyses pointed at an association between the 
SSQ and List Total (r = .541); Category Fluency (r = .381) and QCAE-CES (r = .684), 
suggesting that verbal function was associated with impaired performance on the 
SSQ, and that performance on these tasks was interdependent.  
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A shared component across the SSQ, Category Fluency and QCAE-CES was the 
social narrative embedded within the cognitive linguistic processing demands of 
each test. Successful performance on these tests requires the capacity to hold in 
mind the semantic arc of the statements, in order to generate an answer to the 
questions. The above results may point to a specific difficulty with non-literal 
linguistic processing in this cohort. Perspectives from the field of cognitive linguistics 
may be pertinent here, with regards to the role of non-literal language in social 
communication processes. Landau et al.  (2010) explain that people make sense of 
the world partly through conceptual metaphors, which enable them to understand 
complex abstract social concepts through their understanding of more concrete 
concepts. Thus, far aside from being simply adornments of language, the authors 
argue that conceptual metaphors are cognitive mechanisms which play a key role in 
social cognition.  
4.2.2.3. QCAE Subscales 
Group performance fell in the ‘average’ range for both QCAE subscales. 
Furthermore, the two subscales did not correlate with each other (r = .259); 
suggesting relative independence, in this sample. This supports Reniers et al’s 
(2011) view of empathy as multifactorial, and the construction of each subscale to 
tap into differentiated components of the construct. 
Of note, the QCAE-CES also correlated with reading (r = .525), List Total (r = .522) 
Story Immediate (r = .378), and Category Fluency (r = .393); identifying (perhaps in a 
similar manner to the SSQ) a relationship between specific non-literal linguistic 
components of these tests.  
4.2.3. Additional Correlations between Variables 
4.2.3.1. RMET and SSQ 
The correlational analysis failed to find an association between group-level 
performance on the RMET and SSQ (r = .013). This finding was in keeping with 
other findings in the literature regarding ToM, which have also failed to find 
relationship between the RMET and other social-script based assessments of 
cognitive ToM similar to the SSQ (Brent, Rios, Happe, & Charman, 2004; Homer et 
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al., 2013; Ireland, 2011; Kaland, Callesen, Miller-Nielsen, Mortensen, & Smith, 
2008). As asserted by Ireland (2011) and Brent et al. (2004), it is possible that this 
finding reflects the different cognitive mechanisms required by each test, potentially 
reflecting their focus on ‘cognitive’ or ‘affective’ components of ToM, as discussed 
below. 
As a test of affective ToM; the RMET concerns the social-perceptual understanding 
of non-verbal emotional processing. Successful performance requires the subject to 
have intact visuo-spatial function in order to scan, perceive and understand the 
information in their visual field. As a test of cognitive ToM; the SSQ concerns explicit 
mentalising skills. Successful performance requires intact language and memory 
based mechanisms, with participants required to comprehend and hold in mind non-
literal social narratives. As argued earlier in the discussion, this test relies on a host 
of different cognitive mechanisms, particularly non-literal linguistic function and 
reading ability; areas of ability which were found to be mildly declined and 
interdependent in the current cohort.  
As such, these findings support the idea that the two tests are assessing different 
mechanisms involved in ToM abilities. Unlike Ireland (2011) and Homer et al. (2013), 
this study found that the cohort of people with HIV infection were impaired across 
both tests – rather than just the affective ToM. Given the small sample size it is not 
possible to interpret this observation and further research with larger sample 
numbers are required before this trend can be generalised.  
4.2.3.2. Mood 
Moderate negative correlations between the HADS and the SSQ (-.482) and QCAE-
CES (r = -.462) revealed that participants who reported lower rates of mood 
disturbance were more like to perform highly on these measures. Conversely, the 
relationship between the HADS and RMET went the other way; that is; the more 
anxious or depressed they were, the more likely they were to accurately perceive the 
emotional state of others.  The findings of Chepenik et al. (2007) may offer some 
insight into the above findings; the authors reported that low mood was shown to 
influence memory for emotional words and facial emotion recognition, but not other 
cognitive processes; identifying a specific influence of mood on emotion-related 
86 
 
cognitive processes.  Although this might explain why the HADS score was found to 
correlate with the SSQ and QCAE but not other cognitive tests, it does not explain 
the absence of a correlation with QCAE-AES, or the positive correlation with the 
RMET.   
4.2.3.3. Education  
As would be expected, education correlated highly with the WTAR (r = .741) as well 
as List Total (.403), Story Immediate (r = .618), SSQ (r = .444) and QCAE-CES (r = 
.401). This is in keeping with the shared language component of these tests. 
Contrary to the findings of Ireland (2011), education was not found to be related to 
performance on the RMET. 
4.3. Discussion of the Individual Profile Analyses 
As well as exploring the heterogeneity of the sample, the Individual Profile Analysis 
allowed for an exploration of the extent to which group differences were reflected in 
individual scores; allowing for participant’s cognitive profiles to be located in their 
social contexts. This was particularly appropriate given large standard deviations 
associated with the subtest means. 
4.3.1. HAND 
Participants were categorised into one of four types (ANI, MCD, HAD, INOS) for the 
initial purpose of case analysis profiling only. Three participants reported subjective 
cognitive complaints but demonstrated no clear impairment on testing (INOS). Eight 
participants showed cognitive decline consistent with ANI, of which one had co-
morbid severe anxiety. Four participants showed cognitive and functional 
impairments consistent with MND, of which reported co-morbid severe anxiety. 
Finally, one participant showed cognitive and functional impairments consistent with 
HAD, and they also had severe co-morbid depression. This is broadly consistent with 
the aforementioned trends in the literature which identify that milder forms of HAND 
are more prevalent in the post cART-era, even amongst a diverse sample. 
4.3.2. Social Cognition 
The Individual Profile Analysis revealed that a total of 13 participants demonstrated 
impaired performance on both the RMET and SSQ. This was consistent with the 
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group-level analysis; demonstrating impaired performance across both social 
cognition tests. 
Most notably, the Individual Profile Analysis also revealed that, in contrast to what 
might have been inferred from the group-level analysis, impairment on social 
cognition tests tended to occur alongside cognitive decline in other areas, rather than 
as an isolated deficit. Furthermore, impairment on social cognitive did not show any 
relation to stage of HIV infection.  
4.3.3. Executive Function 
The earlier group-level analyses showed mild decline on the Category Fluency 
subtest only, in the domain of executive function. Further analysis of individual 
profiles revealed that three participants demonstrated impaired performance across 
both verbal and visual tests of executive function1. Five participants demonstrated 
impaired performance on verbal tests of executive function2. And finally, eight 
participants demonstrated intact executive function3. This shows a prevalence of 
impairment at the individual level which was not reflected in the group analysis 
statistics. One possible reason for this discrepancy is that, where no impairment was 
observed, participants typically performed in the ‘high average’ to ‘superior’ range, 
which may have elevated the group subtest mean scores. 
4.3.4. Diversity  
The Individual Profile Analysis revealed a heterogeneous sample; participants 
represented a diverse range of countries-of-birth, ethnicities, cultures, estimated pre-
morbid ability and educational opportunity. It is important to acknowledge that all of 
these demographic and social factors can contribute to the outcome of 
neuropsychological assessments.  
                                            
1 Participant numbers; 5, 8, 12. 
2 Participant numbers; 4, 7, 9, 10, 15. 
3 Participant numbers; 1 2, 3, 6, 11, 13, 14, 16. 
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4.3.5. Education and Language 
Eight participants4 were educated within the UK and spoke English as a first 
language. The other eight participants5 were educated outside of the UK, and all but 
one6 of these had English as a second language. Of note, half of these participants7 
were educated in English-only speaking schools, with their first language being their 
language of communication at home. As a general observation, the four participants8 
who were schooled outside of the UK and educated in their first language, 
demonstrated some of the most disadvantaged cognitive profiles in the cohort. The 
exception to this trend is Participant 8, whose first language was English but 
educated in Jamaica; she showed profound impairments across domains. Whilst it is 
difficult to draw any conclusions from this pattern given the small sample size, it is 
possible that this observation reflects validity issues inherent in the neurocognitive 
tests used in the current study. This concern is revisited in the critical review.  
4.3.6. Physical Co-morbidities 
There was a relatively low presence of physical co-morbid conditions in the sample 
(see Appendix P); with fewer co-morbidities than in similar sized studies with HIV-
positive populations (Ireland, 2011; Johal, 2014) and elsewhere in the literature 
(Cysique et al., 2010). This is likely due to several contextual factors. Firstly, 
participants were recruited from outpatient settings so their health statuses were, by 
virtue of their availability, relatively well-managed. Secondarily, in the post-cART 
context, those treated and cART-adherent, may experience greater periods of 
sustained viral suppression and healthy CD4 count levels, experiencing fewer 
secondary infections and diseases. This observation allows associations between 
performance on neurocognitive tests and cognitive function to be made with more 
confidence. 
                                            
4 Participant numbers; 1, 2, 3, 7, 11, 13, 15, 16. 
5 Participant numbers; 4, 5, 6, 8, 9, 10, 12, 14. 
6 Participant 8 was educated in Jamaica, a Commonwealth Realm and former British Colony which 
has English as its national language.  
7 Participant numbers; 6, 8, 10, 14. 
8 Participant numbers; 4, 5, 9, 12. 
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4.3.7. Psychological Co-morbidities 
A total of three participants reported severe anxiety and/or depression; four reported 
moderate anxiety and/or depression; three reported mild anxiety, and six 
participants’9 scores fell within the normal range. Overall, seven10 participants met 
the threshold for ‘caseness’ (the ‘mild’ category is not included in this division) 
indicating a probable presence of co-morbid anxiety and depression for this 
proportion of the cohort (Snaith, 2003). This is in keeping with the literature which 
reports high - and fluctuating - rates of psychological distress in the clinical 
population (Nakasujja et al., 2010; Rabkin, 2008; Shacham et al., 2012).  
In view of this, it might be deduced that the cohort’s poor performance on the RMET, 
SSQ and low self-report on the QCAE may have been influenced by the co-morbid 
levels of anxiety and depression. However, the extent to which these factors can 
reliably be said to have influenced participants test performance in the current study 
is unclear as the impact of mood on cognitive function and performance on 
neurocognitive tests varies equivocally in the research literature. The group-level 
correlational analysis, as stated, showed the HADS to correlate with performance on 
the RMET, SSQ and QCAE-CES, but not other core tests. However, the individual-
level analysis, in contrast, revealed that impaired performance on social cognitive 
tests did not always occur in the context of high HAD scores, suggesting that – 
although there may well be an association between mood and social ability – these 
variables were not necessarily interdependent in the current study.  
4.4. Critical Review 
4.4.1. Sample Size  
As acknowledged earlier, the current study included a small sample size which, 
although in keeping with exploratory research of this kind, limits the interpretations 
that can be drawn from the current data. In recognition of this fact, the statistical 
power of analyses was not relied upon, in favour of effect size, and results were 
reported as tentative trends within the sample cohort, rather than conclusions 
                                            
9 Participant number; 3, 4, 6, 7, 8, 11. 
10 Participant numbers; 5, 9, 10, 12, 13, 15, 16. 
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appropriate for generalisation to the population. A larger sample would allow for 
more powerful and sophisticated analyses, enabling more direct and specific 
hypothesis testing. 
4.4.2. Normative data  
Manly et al. (2011) argue that, when assessing for HAND, norms should be based 
on a population of HIV-uninfected individuals as closely matched to the HIV-infected 
group as possible. The norms used in the current study, and in much of the literature 
in the field, are those provided by the test publishers, and although adjusted by age, 
and sometimes gender, they are otherwise based on norm groups which do not 
reflect the ethnic, racial, educational and cultural diversity of the clinical population of 
people living with HIV in this country (Heaton et al., 2015) . Therefore, the extent to 
which tests scores can be meaningfully compared to them is a concern, and 
presents a major limitation in the group-level analysis of the current study and 
literature as a whole. However, the Individual Profile Analysis was less affected by 
these limitations, as participants were principally compared to themselves and not a 
normative groups. Nonetheless, the lack of representative demographic variables in 
the normative data increases the risk of cognitive impairment being over-diagnosed 
for certain individuals and groups.  
More recently, efforts have been made to develop appropriate norms which more 
adequately reflect the demographic spread of the HIV clinical population (Manly et 
al., 2011), however, this endeavour in itself has been problematic due to difficulties 
involved in controlling for the influence of various co-morbidities on test performance 
in normative groups.   
4.4.3. Factors affecting Performance; Cross-cultural Limitations 
Consideration should be given to some of the inherent limitations in neurocognitive 
assessment and interpretation. The majority of neurocognitive tests carry the culture 
of white middle-class English-as-first language British and North American people, 
and, thereby, give people from these groups an advantage over test-takers whose 
socialization and life experiences have been different (Brown, Reynolds, & Whitaker, 
1999; He & Vijver, 2012). This has implications for test score interpretation – as 
some people may perform poorly on the tests for reasons separate to cognitive 
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dysfunction – and can lead to false positives in diagnostic assessments, and over-
reporting of deficits in people from certain backgrounds and groups. This is 
particularly pertinent issue for research in the field of HAND given the cultural-
linguistic diversity across people living with HIV in the UK (Aiken & Lever, 2010; 
Anderson, 2008).  
Cultural bias in neurocognitive testing is located in both the test content, and the test 
processes. For example, successful completion of the Picture Naming subtest in the 
RBANS relies on the participant having had exposure to, and familiarity with, certain 
objects and entities (e.g., a cannon, or a trumpet); demonstrating cultural bias in the 
test content. Furthermore, neurocognitive assessments as a whole require particular 
‘thinking styles’ or behavioural patterns which may be more common in some 
cultures than others; for example, the process of sitting in a room with a unknown 
professional administering paper tests may be more common to people who have 
grown up in a paternalistic healthcare system.  
With regards to educational bias, the Individual Profile Analysis revealed that the 
three subjects with the most impaired cognitive profiles were also from non-western 
backgrounds, born and educated outside of the UK, in languages other than English. 
A relevant concern here is that whilst educational attainment is an important factor in 
the interpretation of cognitive test scores, total years of education may not be equal 
to educational quality among different racial/ethnic populations, and the use of it as 
such may lead to inflated impairment rates among said groups  (Ryan et al., 2005). 
Pereda et al (2000) reported that people who were schooled in countries others than 
the UK and USA generally performed poorer than those who were schooled in the 
West. The reasons for this are likely to be many and varied, including years of 
education, educational quality and approaches, and cultural and language factors. It 
is also possible cognitive reserve hypothesis can be drawn upon here. Education is 
one of many factors which can contribute towards the accumulation of positive 
cognitive reserve; as well as positive attachment histories, perinatal development 
and developmental history, nutrition and health and stress, to name but a few 
(Yaakov Stern, 2009).  
Future research can partly account for these limitations by employing culturally 
adjusted neuropsychological measures which offer reading material which has been 
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translated into the participant’s first-language; uses appropriate stimulus materials; 
and, uses normative data for demographically matched populations (Fletcher-
Janzen, Strickland, & Reynolds, 2013) .  
4.4.4. Assessment of Mood  
Consideration here should also be given to the terms 'depression' and ‘anxiety’ 
which hitherto have been employed in an uncritical, arguably essentialist, manner. It 
is beyond the scope of this work to provide a suitable review of the socio-historical 
context of these terms, but it is, nonetheless, important to consider what is being 
spoken about when such words are employed. As well as being umbrella terms for a 
host of putative disorders in psychiatric discourse, the terms anxiety and depression 
are used in everyday parlance for a variety of states of distress. And it is in line with 
the former, that this study has used these terms.  
The HADS was chosen here, as part of a pragmatic endeavour: the standardised 
and validated nature of the tool was of practical use to the research design, and 
allowed mood to be included in the analysis and reported in such a way so as to be 
considered valid and reliable. Although its relative brevity was an advantage for the 
current study, it also served as a limitation in the extent to which it may not offer a 
sufficiently comprehensive assessment of mood. Furthermore, the measure is limited 
in its specific focus on the loss of pleasure response [anhedonia] which is one of the 
two obligatory conditions for the formal classification of 'major depressive disorder' 
(Snaith, 2003) at the sacrifice of other states/sources of mood related distress. 
Future research might select an additional or alternative standardised measure with 
which to, more thoroughly, assess the milieu of subjective difficulties which may 
influence cognition and performance of neurocognitive tests.  
4.4.5. Test Materials 
Manchester et al. (2004) argue that one of the major limitations of neurocognitive 
assessments are their lack of ecologic validity when assessing executive functioning. 
Although this critique can, invariably, be applied to the assessment of any cognitive 
domain, it is a particularly relevant to the assessment of social cognition. Dealing 
with competing social demands in the real world requires both specific social 
processes and general cognitive mechanisms that may not be tested in the clinical 
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assessment environment. Furthermore, assessments are generally conducted within 
calm and quiet testing rooms where the participant is clearly presented with the 
target task, instructions, and parameters (e.g., time restrictions, rules, start and end 
times). Under these conditions, a participant may achieve a score that indicates no 
cognitive dysfunction, despite experiencing difficulties in daily life (Sbordone, 1996).  
The SSQ requires that participants make accurate inferences about fictional-other’s 
thoughts and feelings in hypothetical social stories; one’s ability to succeed at this 
exercise is taken to reflect something of their explicit mentalising skills. Upon 
inspection of the SSQ, limitations are revealed with regards to the (arguably, dated) 
use of social norms and social lexicon. As with many tests, successful performance 
relies on the participant having been sufficiently socialised in specific social norms in 
order for them to identify the requisite violations of social norms. Participants from a 
younger generation, or those from different cultural backgrounds, may be less 
familiar with some of the encounters described, or finer social nuances in the 
language, and thus their performance may not be representative of their social ability 
– but rather their familiarity with a now non-dominant expression of English culture.  
These limitations are not specific to the SSQ, but shared across many of the social 
cognition assessment measures available today. This highlights the need for the 
development of contemporary tests in the field of social cognition, including tests of 
ToM, which can be validated for use in research. With this is mind, it is 
recommended that future research into social cognition in HAND should consider 
using four different measures to those used here; two different tests of (affective and 
cognitive) ToM to further explore trends as well as construct validity; and, two non-
ToM tests of social ability to explore the breadth of the trends in social cognition 
impairment. One such test of ToM, to replace the RMET, could be Begeer et al’s 
(2010) Instructor Task as discussed in the Introduction. 
The extent to which future research is designed with ecological validity in mind will 
depend on the research rationale. That is, whether the cognitive assessment is 
designed with the intent to assess for dysfunction or to predict everyday functioning. 
Although these are not necessarily mutually exclusive, their relative separation is 
often cited as the reason for the absence of the verisimilitude approach in traditional 
neurocognitive test materials (Spooner & Pachana, 2006).  
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Finally, the addition of a qualitative research component into research of this kind 
would offer a contrasting form of assessment with which to triangulate the study 
findings, and enable an exploration of constructions: in keeping with a critical realist 
perspective. 
4.5. Clinical Implications and Summary of Recommendations  
Although the underlying cognitive mechanisms and specific processes of social 
cognition are yet to be fully understood, we can be nevertheless be confident that as 
human beings in this society, our ability to comprehend and understand the abstract 
nuances of our social world is fundamentally important for our capacity to navigate 
daily life as adeptly as is possible. The current study demonstrated disadvantaged 
performance on two social cognition tests in a culturally diverse cohort of people with 
HIV infection, most of whom are cART-adherent with an undetectable viral load, with 
no comparable areas of neurocognitive decline across core areas of cognition, 
including executive function. Assuming that impairments on these measures 
demonstrates a reliable underlying difficultly, these trends may translate as real life 
difficulty with emotion recognition and coping with the social complexities of 
communicative exchanges in everyday life and, if undetected, may have pervasive 
and disabling influences on peoples social communication and interpersonal 
relationships.  
Although the findings in the current study are too tentative to make concrete 
recommendations to national clinical guidelines or practice, they may still extend a 
pragmatic contribution to clinical knowledge. By this, the researcher refers to the 
potential of these findings to promote the extension of empathy towards patients who 
show complex emotional and behavioural presentations in outpatient settings by 
contributing to the way in which such presentations can be made sense of by 
clinicians. This is particularly significant because, at present, social cognition 
impairments may not be identified as indicative of HIV-related health consequences. 
Instead, patients conduct may become understood through the lens of reductive 
labels such as ‘difficult patient’ or ‘treatment resistant’ and, in this way, the 
understandable and meaningful expressions of cognitive impairment – that is, 
properties of the illness – risk being constructed as a problem in the patient’s pre-
morbid ‘personality’. Through increased awareness of the potential emotional and 
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behavioural sequalae of HAND, dissemination of these ideas and findings can seek 
to increase awareness, understanding of, and empathy towards our patients, which, 
even in light of the tentative nature of these findings, can only be a worthwhile 
pursuit.  
As well as contributing towards professional awareness, the current findings might 
contribute to the provision of ‘psycho-education’ within clinical discussions, as part 
of, or separate to, wider neurorehabilitation programmes for HAND. In their 
investigation into the relative benefits of ‘meta-knowledge’ (that is, patients’ 
awareness of illness and their conscious knowledge of their own cognitive 
processes) Casaletto et al. (2016) argue that improved metacognition (i.e., 
awareness of neurocognitive impairments) is significantly associated with greater 
engagement with and motivation for treatment and reduced risk of early attrition. 
With this in mind, these findings might encourage a dialogue around the potential 
implications of pre-frontal lobe impairments and patients experience of cognitive 
changes, specific to social communication and emotion recognition, or otherwise 
(given the heterogeneous nature of HAND). The potential therapeutic benefits of 
psycho-education in listening to patients concerns, normalising anxieties and 
difficulties, and providing support, were witnessed throughout the process of the 
research methodology, where the researcher provided each participant with tailored 
feedback for test results and (where necessary) cognitive rehabilitation techniques. It 
is, however, important to practice caution when using the language of ‘impairments’ 
and ‘deficits’ in dialogue with patients, acknowledging the potential of such words to 
cause distress and influence negative cognitive schemas or self-narratives.  
Together with previous research (Homer et al., 2013; Ireland, 2011) these findings 
advance the case for further exploratory research into the area of social cognition 
impairments in HAND. To summarise the recommendations identified in the critical 
review; future research should seek to replicate the exploratory approach using 
different and improved measures of social cognition with a view to explore construct 
validity, as well as to further explore the tentative trends reported in the current 
study.  
Should said trends continue to emerge, then the rationale for more well-resourced 
research with a larger sample can be made, to explore areas of impairment with 
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more clarity and statistical power. Such research will contribute to the evidence base 
regarding the neurocognitive consequences of HAND, with implications for clinical 
practice including; the extension of neuropsychological assessments of HAND to 
include an assessment of social cognition; and, informing the development of neuro-
rehabilitative therapy programmes for HAND. 
4.6. Concluding Statement  
In seeking to explore the existence of social cognition impairments in HAND, the 
researcher hoped to contribute towards a relatively new and emerging area of 
research located within the wider understanding of the neuropsychological 
consequences of HIV. Specific neuropsychological measures were chosen to allow 
the findings to be compared in a meaningful way to the tentative trends identified in 
previous small-scale research of this kind; matching up theoretical constructs and 
assessment techniques. The present sample demonstrated clear disadvantages in 
their performance on the two social cognition measures and these findings were 
interpreted both in comparison to normative scores, and in context, alongside the 
sample’s educational and cultural circumstances, and individual life-experiences, 
and the wider literature regarding relevant PFC-implicated neurological conditions. 
Although the small sample size in the current study limits any concrete conclusions 
from being drawn from the results, these findings make a clear case for further well-
resourced research into the emotional and behavioural consequences of HAND, and 
point to several potential clinical recommendations for consideration by clinical 
teams. What it means to live with HIV in the UK has drastically changed in the last 
three decades: with the health-consequences of HIV infection shifting from life-
limiting, to chronic and manageable, it has never been more important to investigate 
the potential neuropsychological impact of HIV infection in order to adequately and 
sensitively respond to the varied needs of service-users.  
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Appendix A Revised HAND Criteria 
Adapted from (A. Antinori et al., 2007).  
HIV-associated asymptomatic neurocognitive impairment (ANI) 
 Acquired impairment in cognitive functioning, involving at least two ability 
domains, documented by performance of at least 1.0 SD below the mean for 
age-education-appropriate norms on standardized neuropsychological tests. 
The neuropsychological assessment must survey at least the following 
abilities: verbal/language; attention/working memory; abstraction/executive; 
memory (learning; recall); speed of information processing; sensory-
perceptual. 
 The cognitive impairment does not interfere with everyday functioning.  
 The cognitive impairment does not meet criteria for delirium or dementia.  
 There is no evidence of another pre-existing cause for the ANI. 
HIV-1-associated mild neurocognitive disorder (MND) 
 Acquired impairment in cognitive functioning, involving at least two ability 
domains, documented by performance of at least 1.0 SD below the mean for 
age-education-appropriate norms on standardized neuropsychological tests. 
The neuropsychological assessment must survey at least the following 
abilities: verbal/language; attention/working memory; abstraction/executive; 
memory (learning; recall); speed of information processing; sensory-
perceptual, motor skills. 
 The cognitive impairment produces at least mild interference in daily 
functioning (at least one of the following): a 
 Self-report of reduced mental acuity, inefficiency in work, homemaking, or 
social functioning. 
 The cognitive impairment does not meet criteria for delirium or dementia.  
 There is no evidence of another pre-existing cause for the MND. 
HIV-1-associated dementia (HAD) 
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 Marked acquired impairment in cognitive functioning, involving at least two 
ability domains; typically the impairment is in multiple domains, especially in 
learning of new information, slowed information processing, and defective 
attention/concentration. The cognitive impairment must be ascertained by 
neuropsychological testing with at least two domains 2 SD or greater than 
demographically corrected means. (Note that where neuropsychological 
testing is not available, standard neurological evaluation and simple bedside 
testing may be used, but this should be done as indicated in algorithm; see 
below). 
 The pattern of cognitive impairment does not meet criteria for delirium (e.g., 
clouding of consciousness is not a prominent feature); or, if delirium is 
present, criteria for dementia need to have been met on a prior examination 
when delirium was not present. 
 There is no evidence of a co-morbid cause for the dementia. 
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Appendix B UEL Research Registration Confirmation Letter 
The researcher’s and signatory’s contact details have been redacted in the following 
document. 
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Appendix C Ethics Committee Documentation  
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Appendix D NHS (NRES) Provisional Approval Letter 
The researcher’s and signatory’s contact details have been redacted in the following 
document.
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Appendix E NHS (NRES) Full Approval Letter  
The researcher’s and signatory’s contact details have been redacted in the following 
document.
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Appendix F Site A: Research Approval Letter  
The researcher’s personal contact details, Trust logos, and specific Service details 
have been redacted in the following document.
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Appendix G Site B: Research Approval Letter  
The researcher’s personal contact details, Trust logos, and specific Service details 
have been redacted in the following document.
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Appendix H Site B: Scientific Peer Review Provisional Letter 
The researcher’s personal contact details, Trust logos, and specific Service details 
have been redacted in the following document. 
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Appendix I Researcher Response to Appendix H: Proposed 
Adjustments 
The following letter shows the researchers response to questions raised by the 
Scientific Peer Review, as shown in the previous Appendix item. The researcher’s 
personal contact details, Trust logos, and specific Service details have been 
redacted to protect the anonymity of the participants. 
 
*ADDRESS DELETED* 
 
 
*ADRESS DELETED* 
20th July 2015 
Dear Dr X, 
Study number: 206 
Study Title: Social cognition and HIV: exploring the profile of cognitive impairments in HIV-
associated Neurocognitive Disorders (HAND)  
Thank you for your letter dated 14th July 2015 in which you summarised the comments raised by the 
reviewers from the I&I Internal Peer Review Group for the aforementioned study. I am grateful to you 
and the reviewers for your time and detailed comments.  
I hope this letter serves to adequately address and clarify the concerns and questions about the 
protocol & implementation plans of this research study within your service. I look forward to your 
response.  
 “Who is the local lead/supervisor for this study?” 
The local lead and on-site supervisor for the study with be Dr Alison Jones, Clinical Psychologist. The 
study will also be supervised off-site by experienced neuropsychologist Dr Matthew Jones-Chesters 
at the University of East London, who will both monitor the progress of the study as well as offer 
clinical supervision.  
 “How will patients be identified?” 
Neuropsychological assessments are routine practice at the Ambrose King Centre, and the service 
has a waiting list of patients waiting to receive this specific service. Potential participants will be 
identified from this waiting list. My research protocol involves conducting the same routine battery of 
tests that would be used in this clinical setting, with the addition of two extra questionnaires. I will 
therefore be able to provide the neuropsychological assessment to meet the identified clinical need, 
with the addition of two extra tests of social cognition in order to conduct my research. I will provide a 
neuropsychological report, setting out the client’s strengths and weaknesses, and will include 
management and/or rehabilitation recommendations (subject to participant consent). 
I have spoken to staff in the team about the practicalities of me identifying patients from this list who 
meet the study criteria. Suitability for participation will always be done in conjunction with the 
professional opinion of the senior clinician on site. I will liaise with Dr Alison Jones (Clinical 
Psychologist) and the team at the Ambrose King Centre to discuss which potential participants from 
the waiting list they feel may be appropriate for me to approach, and I will then contact the patient by 
phone and explain to them the study in line with the information provided in the Patient Information 
Form. 
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 “How will psychological issues which might emerge as a result of participating be addressed?”  
The likelihood of participants feeling distressed after cognitive testing is very low. Any potential risks 
are discussed in the information letter to ensure transparency on behalf of the researcher and 
informed consent from the participant. For example, the participant information sheet states the 
potential of fatigue during the assessment, and the efforts to minimise this are outlined such as taking 
regular breaks, and organising the assessment over two days if necessary.  
In addition to the aforementioned precautions, participants will be monitored by the researcher for 
signs of fatigue and/or frustration throughout the testing process. If necessary, breaks will be offered 
as will reminders of the participant’s right to withdraw from the study. If anything of significant concern 
is evident throughout the performance (e.g. disorientation, unable to do a simple task) the clinical 
team will be informed immediately.  
 “Participants might have questions, concerns about HIV and cognitive functioning. Consider how 
you might address such questions/concerns.” 
A verbal debrief at the end of testing will be provided to participants in further effort to minimise 
psychological harm and/distress to participants as well as make the process a potentially enjoyable 
rewarding and educational one in which to take part. In the verbal debrief the researcher will be able 
to answer any questions the participants may have about the content of the tests, and the participants 
will receive a neuropsychological report once the tests have been scored.  
If the participant has any questions about their illness or cognitive functioning the researcher can 
signpost the participant to discuss these with their specialist care team, or, with the participants 
consent, chose to directly pass these concerns on behalf of the participant to the clinical team for 
further assessment and support. The researcher will also have to hand the contact details of two 
charity organisations which offer local non-directive support as well as confidential psychological 
support for the participant to take away with them and use in their own time should they wish.  
The aforementioned details will look like this:  
Support services for people living with HIV and/or AIDS 
If you would like information or support regarding living with HIV or AIDs you can contact staff at 
Ambrose King Centre, or alternatively please find some information below about local charities you 
can access. If you have access to the internet you can find out more about these services online and 
contact them by email, or you can call the numbers below. 
Terrance Higgins Trust Tel: 0808 802 1221. 
Their number is free to call from all UK landlines and most UK mobiles and will not appear on your 
telephone bill. When you ring you’ll hear a menu system which will give you options to: listen to 
recorded information, leave a message to be called back in another language, hold the line if you’d 
like to speak an adviser. 
PositivelyUK  Tel: 0207 713 0444 
Their helpline is open from 10am-4pm, Monday to Friday. You can call to speak to one of their 
support team who are living with HIV themselves. 
 “Have we confirmed that there is space?” 
I have spoken with my on-site contact *name deleted* Chartered Clinical Psychologist at the service 
about the space and feasibility of my research being conducting with the service. It was felt that there 
was suitable clinical space in the service to facilitate the research in such a way that the research 
would not be burdensome or obstructive in any way to the existing clinical practice, but instead 
facilitative of an existing need for neuropsychological assessments as part of existing patients care 
package in the service.  
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 “Recruitment plans: These are unclear. It is stated that, “Participants will be required to have 
diagnosis of HIV but not HAND.” However, it is not clear who you wish to recruit as it seems that 
you are looking for participants with HAND and this potentially reads as if HAND is an exclusion 
criterion. (Antiretroviral treatment status is not mentioned and this may theoretically impact on 
NCI.)” 
The referral criteria for this study is that individuals must have diagnosed HIV infection, be able to 
understand spoken and written English, not require an interpreter, and have no active psychosis or 
substance use. A pre-existing diagnosis of HIV-associated neurological disorder (HAND) is welcome 
but not necessary due to the evidence that Asymptomatic Neurocognitive Impairment (the most 
common type of HAND) is asymptomatic and therefore likely under-diagnosed in services likes 
Ambrose King Centre where neuropsychological testing is not a mandatory. If many people with 
HAND are undiagnosed, only recruiting those with a diagnosis would severely limit the sample and 
risk making it more unrepresentative. 
Given that participants will be identified off the waiting list of patients waiting for neurocognitive 
assessment, it follows that all potential participants will have some form of neurocognitive complaint 
which has warranted their referral onto the waiting list. As such, all participants will be assumed to 
have some cognitive impairment, whether it is formally diagnosed or not.   
Antiretroviral treatment status and CD4 count will certainly be documented, but not controlled.  
 “Are you going to compare symptomatic individuals with each of the 4 categories of NCI (i.e. ANI, 
MCD, HAD, I-NOS as defined in methods)? If so, who are you comparing with – between NCI 
groups or against patients without HAND?” 
The primary focus of the research questions to observe the differences within a sample of individuals 
with HIV with varying levels of cognitive impairment, and since no data is intended to be manipulated, 
nor any trials or interventions offered, no control group was considered necessary.  
Participants will be categorised into one of four types (ANI, MCD, HAD, INOS) for the initial purpose 
of demographic profiling only.  
 “What about confounding due to the duration of HIV, co-existing morbidities, ethnicity?”  
Previous research studies which have initially sought to recruit only participants with 'pure' neuro-
cognitive difficulties and no other confounding variables have reported that they found that individuals 
such as these are very rare, particularly in the area of London (for example, Ireland, 2010). In such 
studies it has been necessary to change the initial exclusion criteria so that participants are not 
excluded based on co-morbidities or ethnicity, with the aim of both facilitating recruitment and 
encouraging a more representative sample. This is consistent with the literature which suggests that 
less than 10% of individuals with HAND are considered to have no co-morbidities (Heaton, Franklin, 
Clifford, Woods, & Rivera Mindt, 2009). As such, it was felt that controlling or excluding such criteria 
from the data set would risk not only restricting the sample size, but also reducing representative 
nature of sample to the identified clinical population.  
Unlike other neurodegenerative disorders such as Alzheimer’s, HAND is not invariably progressive 
and is therefore not an immutable diagnosis. Current literature reports mixed findings regarding the 
relationship between duration of HIV and severity of impairment,  reporting that neurocognitive 
impairments can fluctuate over time regardless of duration of infection (Robertson et al., 2007), with 
longitudinal studies reporting 50% of those with HAND showing fluctuations in the degree of 
neurocognitive impairment. For this reason,  
HIV/AIDs duration and severity will be noted but participants will not be excluded or included based 
on this factor.  
In the development of this study I had initially planned to exclude participants with a diagnosis of 
Hepatitis C and current infections. However, following consultation with Dr Matthew Jones Chesters 
(off site supervisor) and Dr Alison Jones (on site supervisor if study is approved) it was agreed 
instead to drop these exclusion criteria for the reasons stated in the first paragraph of this section, as 
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it would significantly reduce the pool of potential participants to the point that the remaining pool 
become unrepresentative of the clinical reality.  
 “What about a comparator group with a different long term conditions?” 
A comparator group may serve to enhance the breadth of the study and the options of statistical 
analyses to analyse the data, but the additional input required to operationalise and implement this 
recommendation is unfortunately outside of the scope of this particular project due to the limited 
availability of time and resources.  
  “Statistical analysis” 
This study will employ a cross-sectional correlational cohort design (that is, a ‘non-manipulation’ 
study) and this will enable an exploration of a given number of variables within a given time frame 
within a representative group. The variables of particular interest are social cognition and executive 
function and their relationship to general cognitive functioning in a group of individuals with HIV. This 
approach was considered best to fit the research questions since the aim was to observe and explore 
relationships within this sample and no data it intended to be manipulated. 
A single case series level of analysis will be used to enable a more detailed and descriptive analysis 
of the data and the individuals within the sample. 
 “Ethics: It seems that you may be giving a diagnosis (i.e. ANI, MCD, HAD, I-NOS) to individuals 
who may not previously have a HAND diagnosis or who may be asymptomatic.” 
The site-specific assessment procedure required in order to give a diagnosis of HAND is not part of 
the project methodology and as such is not an outcome of participation in the study. If the basic 
cognitive assessment tools used in the methodology indicate an existing cognitive impairment 
requiring more depth assessment then this will be documented in the form of a Neuropsychological 
Report outlining cognitive strengths and weaknesses, rehabilitation recommendations and 
suggestions for further testing – with consent of the participant. Any necessary further assessment 
and care-planning will be managed within the specialist team in line with their operational policy, and 
the Clinical Psychologists in the team will be able to use my neuropsychological report as a baseline 
for further assessment and continuation of care within the service.  
 “How was the sample size derived? CIs? / Provide rationale for the number of participants 
recruited. / Do you have a large enough sample to apply statistical analysis or would this be more 
appropriate as a descriptive study?” 
To decide the sample size, consideration was given to a number of factors including the time taken to 
collect the data, the time frame of the study, the likely availability of people, the work time equivalent 
hours available for data collection, and the typical sample size in study of this type.  
Given my plan for how participants would be identified (off a waiting list for patients awaiting 
neuropsychological tests) I would hope to obtain a broadly representative sample and the research 
methodology outlines a process of collecting data is labour-intensive which will limit sample size. 
Neuropsychological research frequently involves small Ns, and this is consistent with the numbers 
recruited for similar previous research projects which have been conducted with individuals with HIV 
in similar settings and with similar time restrictions. 
In this instance, a power analysis is not appropriate as I am conducting a descriptive study and 
therefore not doing the type of analysis that requires one.  
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Appendix J Site B: Scientific Peer Review Acceptance Letter  
The researcher’s personal contact details, Trust logos, and specific Service details 
have been redacted in the following document. 
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Appendix K Participant Information Sheet  
The following document was used in both site A and site B. The text remained the 
same across sites but the logo and other identifiers changed depending on the site. 
NHS Trust logos and specific service details have been removed to protect the 
anonymity of the participants. 
 
HIV Neuropsychology Research Study 
Social reasoning in People Living with HIV-Infection 
 
PARTICIPANT INVITATION and INFORMATION 
V2: 11.06.2015 
 
The purpose of this letter is to provide you with the information you need before deciding whether to 
participate in this research. My name is *name deleted* and I am the chief researcher. My contact 
details can be found below. 
 
What is this research about? 
This study aims to explore the impact that HIV infection may have on the way our brains work.  Our 
brains are involved in numerous processes, including our ability to think, remember, judge, learn, and 
interact together as social beings. Different physical health conditions can affect our brains and 
therefore have an impact on how our brains perform on some of these skills. 
 
What do I have to do?  
You will complete a collection of short exercises which explore a wide range of skills and abilities like 
memory, language, visual-spatial ability and social skills. You will be asked to give verbal answers to 
questions asked by me, complete pen-and-paper exercises under timed conditions, and there will also 
be a questionnaire to fill in. These tests are quite common and are used routinely in other services as 
part of routine Neuropsychological evaluations.  
 
You will be asked to complete:  
- A questionnaire about social skills 
- A set of short exercises for general skills like memory, language and visual-spatial skills 
- A word-reading exercise 
- Two exercises about social skills  
 
The tests will take approximately 1.5 hours and you will be offered a break in the middle.  If you prefer 
we can do two shorter assessments over two days. The tests which require verbal answers will be 
audio recorded to ensure your performance can be accurately scored. 
 
Location 
Testing will take place in one of the private rooms at … at a time and date agreed by you. 
 
What will I gain from being involved?  
Doing these tests can provide you with: 
An enhanced understanding of your brain’s strengths and weaknesses. 
Information that will contribute towards your treatment plan and you and your health care professional 
better understand and treat your difficulties.  
 
Who is organizing and funding the study? 
The study was organized by myself and Dr Matthew Jones Chesters in collaboration with University of 
East London and *NHS Trust service deleted*, as part of my doctoral thesis that will be submitted to 
the University of East London. 
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What will happen to the results? 
We will write a summary of your test results, give you a copy of this, and if you wish discuss the 
results with you. The researcher will be unable to feedback immediately after testing as they will need 
to time to process your results. 
You may also want your consultant (or other member of staff) to receive a copy to help inform your 
treatment but this will only be done with your permission.  
 
Results from this research will be made anonymous and incorporated into a thesis which may be 
published in an academic journal in the future. No identifiable data about you will be included in any 
report or publication.  
 
Will my study data and research participation be kept confidential? 
All the information you provide for the purposes of the study will be anonymised, kept strictly 
confidential, and kept separately from personal information the service holds about you.  Score sheets 
and consent forms will be stored in a secure location. Once the scores from your tests have been put 
onto the computer there will be no identifiable information which links you to the information. 
Confidentiality will only be broken if you tell us that you plan to harm yourself or somebody else. In 
such cases, we would discuss with you who would be best placed to help and tell people involved in 
your care. 
 
Are there any risks involved? 
Neither the questions nor procedures are in any way harmful. Sometimes, participants feel tired 
during or after the tests due to having concentrated for a longer time than normal, this is normal and 
can be reduced by taking regular breaks. You may also find yourself getting frustrated with certain 
tasks, this too is completely normal and I will be there to assist you. 
 
What if something goes wrong?  
You can direct any complaints to me or Dr Mark Finn Chair of the Research Ethics Committee at 
University East London (contact details below). In the unlikely event that anyone is harmed, the study 
is has indemnity cover from the University of East London. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion by 
NRES Committee South Central - Hampshire A Research Ethics Committee. 
 
Do I have to take part? 
No. Your participation is voluntary. Should you choose not to participate, this will have no 
consequences for your relationship with staff at the service.   
 
If you decide to take part but later change your mind, you are free to withdraw from the study at any 
time and your information will be deleted. However, the researcher reserves the right to use your 
anonymised data in the write-up of the study and any further analysis. 
 
What happens now? 
If you are happy to continue you will be asked to sign a consent form. 
 
If you have any questions or concerns about how the study has been conducted, please contact me, 
Lucy Butler Trainee Clinical Psychologist, at *contact details deleted* 
 
or  
 
Chair of the School of Psychology Research Ethics Sub-committee *name and contact details 
deleted* 
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Support services for people living with HIV and/or AIDS 
If you would like information or support regarding living with HIV or AIDs please find some 
information below about local charities. If you have access to the interest you can also find out more 
about these services online and contact them by email. 
Terrance Higgins Trust Tel: 0808 802 1221. 
Their number is free to call from all UK landlines and most UK mobiles and will not appear on your 
telephone bill. When you ring you’ll hear a menu system which will give you options to: listen to 
recorded information, leave a message to be called back in another language, hold the line if you’d 
like to speak an adviser. 
PositivelyUK  Tel: 0207 713 0444 
Their helpline is open from 10am-4pm, Monday to Friday. You can call to speak to one of their 
support team who are living with HIV themselves. 
 
Instructions prior to appointment 
How can I prepare for my evaluation?  What should I bring? 
 If you wear hearing aids or glasses, bring them with you. 
 Take your medication(s) as you normally do, unless your doctor has told you otherwise. 
 Give yourself plenty of time for travel, to find the location, and for parking. 
 Make sure you eat something before you arrive so that you are comfortable until the lunch 
break. 
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Appendix L Participant Consent Form  
The following document was used in both site A and site B. The text remained the 
same across sites but the logo and other identifiers changed depending on the site. 
NHS Trust logos and specific service details have been removed to protect the 
anonymity of the participants. 
 
HIV Neuropsychology Research Study 
Social reasoning in People Living with HIV-Infection 
 
CONSENT FORM 
V2; 11.06.2015 
 
 
Date: 
Participant Identification: 
 
 
 
I confirm I have read and I understand the information sheet dated 
11.06.2015 for this research study and have been given a copy to 
keep. I have had the opportunity to consider the information, ask 
questions, and have had these answered satisfactorily 
 
I understand that my involvement and data in this study will remain 
strictly confidential. I understand the limits to confidentiality e.g. times 
when confidentiality will be broken. 
 
I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving reason and without it affecting my 
care. Should I withdraw, the researcher reserves the right to use my 
anonymous data in the write-up of the study and in any further 
analysis. 
 
I understand that my consultant will be informed of my participation in 
this study. 
 
I consent to my consultant being sent a copy of my results. 
 
I hereby freely and fully consent to participate in the study.  
 
 
__________________ 
 
 
_________________ 
 
 
__________________ 
Participants Name Date Signature 
 
 
_________________ 
 
 
_________________ 
 
 
__________________ 
Researcher Date Signature 
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Appendix M Neuropsychology Test battery  
 
Table 8: Table of Neurocognitive Assessments  
Cognitive Domain/Area of Assessment Subtest 
Premorbid Function WTAR 
Affect Hospital Anxiety and Depression 
Scale (HADS) 
Attention and Information Processing Speed RBANS Digit Span Forward 
RBANS Coding  
Trail Making Part A* 
Immediate Memory RBANS List Learning 
RBANS Story Learning 
Delayed Memory RBANS List Recall  
RBANS List Recognition   
RBANS Story Recall  
RBANS Story Recognition  
RBANS Design Recall 
Language RBANS Picture naming 
DKEFS Semantic Fluency 
WTAR  
Visuo-Spatial Function RBANS Line Orientation 
RBANS Figure Copy  
Executive Function Word Generation – Verbal Fluency DKEFS word generation 
Word Generation – Semantic Fluency DKEFS category generation 
 
Verbal Switching DKEFS verbal switching 
Visual Switching and Sequencing Trail Making Part A and Part B 
Visual Working Memory and Rule 
Detection   
Brixton Test 
Verbal Working Memory RBANS Digit Span Forwards  
RBANS Digit Span Backwards  
Social Cognition Affective Explicit 
Mentalising/Affective ToM 
Social Stories Questionnaire 
Cognitive Explicit 
Mentalising/Affective ToM 
Reading the Eyes in the Mind 
Test 
Empathy 
 
Questionnaire of Cognitive and 
Affective Empathy 
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Appendix N Conversion Table  
Table adapted from RBANS Published Normative Information 
 
Table 9: Conversion Table showing Scaled Scores and Subjective Labels 
%ile 
equiv 
Scaled 
Score 
Label 
>98 
19 
Very Superior 18 
17 
91-97 
16 
Superior  15 
14 
75-90 
13 
High Average 
12 
50-74 
11 
Average 
10 
25-49 
9 
8 
10-24 
7 
Low Average 
6 
2-9 
5 
Below Normal 
4 
<2 
3 
Impaired 
2 
1 Very Impaired 
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Appendix O Correlational Analysis Matrix 
This table demonstrates how the measures of social cognition correlate with each other, as well as the other areas of (group-level) 
impairment, and demographic variables.  
 
Table 10: Non-Parametric Bivariate Correlational Analysis Matrix 
 
*Correlation is significant at the 0.01 level (2-tailed). 
**Correlation is significant at the 0.05 level (2-tailed). 
 
 WTAR Age HAD 
total 
Education List 
Total  
Story 
Imm 
Cat’ 
Fluency 
Figure 
Copy 
RMET SSQ QCAE-
CE 
QCAE-
AE  
WTAR 1.000 .275 -.284 .741** .331 .598* .527* .371 -.024 .387 .535* -.021 
Age .275 1.000 .048 -.085 -.448 -.154 -.171 .061 -.062 -.121 -.106 .028 
HAD -.284 .048 1.000 -.370 -.241 .068 .005 .207 .383 -.482 -.462 .214 
Education  .741** -.085 -.370 1.000 .403 .618* .476 .299 -.151 .444 .401 -.175 
List Total  .331 -.448 -.241 .403 1.000 .652** .730** .390 0.010 .541* .522* .298 
Story Imm .598* -.154 .068 .618* .652** 1.000 .725** .585 -.057 .237 .378 .226 
Cat’ 
Fluency 
.527* -.171 .005 .476 .730** .725** 1.000 .554* -.057 .237 .281 .226 
Figure 
Copy 
.371 .061 .207 .299 .390 .585 .554* 1.000 -.262 .328 .289 .107 
RMET -.024 -.062 .383 -.151 0.010 -.057 -.037 -.262 1.000 .013 -.304 -.042 
SSQ .387 -.121 -.482 .444 .541* .237 .381 .328 .013 1.000 .684** .098 
QCAE-CES  .525* -.106 -.462 .401 .522* .378 .393 .289 -.304 .684** 1.000 .259 
QCAE-AES -.021 .028 .214 -.175 .298 .226 .093 .107 .167 .098 .259 1.000 
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Appendix P Participant Characteristics Table 
Table 11: Table of Participant Characteristics 
 
ID Age Sex Years of 
Educat’n 
Education  cART CD VL WTAR Ethnicity HAD-
A 
HAD-
D 
Co-morbidities 
1 57 M 13 UK Y 575 1 11 White British 12 11 Paternal Alzheimer’s 
 
2 41 M 16 UK Y 512 22174 12 Black British 12 10  
3 33 M 16 UK N 587 42909 11 Black British 8 9 Non-cART 
4 40 F 11 UGANDA Y 529 1 7 Black African 7 10 Past PTSD 
5 48 F 8 SOMALIA Y 76 64216
7 
9 Black African 9 18 Severe Depression  
6 36 F 16 SPAIN Y 441 88608 12 White Spanish 10 13 History of Postnatal 
Depression and mild 
Chrones Disease. 
7 69 M 13 UK Y 418 1 13 White British 8 11 Shingles 
8   49 F 11 JAMAICA Y 954 1 2 Black British 10 12  
9 41 F 6 KENYA Y 594 1 1 Black African 17 12 Hypercholesterolaemia; 
Hysterectomy 
Severe Anxiety  
10 42 F 11 PORTUGAL Y 687 1 8 White 
Portuguese 
14 14 Past Kaposi’s Sarcoma. 
11 49 M 19 UK Y 869 1 13 Black British 11 13  
12 43 F 13 BARUNDI Y 580 1 1 Black British 17 18 History of Trauma 
13 48 M 13 UK Y 704 1 11 White British 18 17 Poor sleep. Past Kaposi's 
sarcoma. Severe Anxiety 
14 24 Male 15 SINGAPORE Y 282 263 13 White Asian 13 14  
15 33 Male 11 UK Y 720 1 8 White British 14 14 Severe adverse cART side 
effects to first regime 
16 50 Male 13 UK Y 806 1 12 White British 14 13  
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